EP3471562A1 - Synthetic compositions comprising human milk oligosaccharides for use the prevention and treatment of disorders - Google Patents
Synthetic compositions comprising human milk oligosaccharides for use the prevention and treatment of disordersInfo
- Publication number
- EP3471562A1 EP3471562A1 EP17812794.0A EP17812794A EP3471562A1 EP 3471562 A1 EP3471562 A1 EP 3471562A1 EP 17812794 A EP17812794 A EP 17812794A EP 3471562 A1 EP3471562 A1 EP 3471562A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- hmos
- human
- cvd
- fucosylated
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 215
- 229920001542 oligosaccharide Polymers 0.000 title claims description 59
- 150000002482 oligosaccharides Chemical class 0.000 title claims description 59
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 53
- 235000020256 human milk Nutrition 0.000 title claims description 47
- 210000004251 human milk Anatomy 0.000 title claims description 45
- 238000011282 treatment Methods 0.000 title description 27
- 208000035475 disorder Diseases 0.000 title description 4
- 230000002265 prevention Effects 0.000 title description 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims abstract description 55
- 230000001603 reducing effect Effects 0.000 claims abstract description 43
- 206010022489 Insulin Resistance Diseases 0.000 claims abstract description 36
- 230000036186 satiety Effects 0.000 claims abstract description 20
- 235000019627 satiety Nutrition 0.000 claims abstract description 20
- 230000003019 stabilising effect Effects 0.000 claims abstract description 16
- 230000001105 regulatory effect Effects 0.000 claims abstract description 14
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 87
- 208000008589 Obesity Diseases 0.000 claims description 87
- 235000020824 obesity Nutrition 0.000 claims description 82
- RBMYDHMFFAVMMM-PLQWBNBWSA-N neolactotetraose Chemical compound O([C@H]1[C@H](O)[C@H]([C@@H](O[C@@H]1CO)O[C@@H]1[C@H]([C@H](O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O)O[C@H](CO)[C@@H]1O)O)NC(=O)C)[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O RBMYDHMFFAVMMM-PLQWBNBWSA-N 0.000 claims description 54
- SNFSYLYCDAVZGP-OLAZETNGSA-N 2'-fucosyllactose Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@H](OC(O)[C@H](O)[C@H]2O)CO)O[C@H](CO)[C@H](O)[C@@H]1O SNFSYLYCDAVZGP-OLAZETNGSA-N 0.000 claims description 53
- SNFSYLYCDAVZGP-UHFFFAOYSA-N UNPD26986 Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(OC(O)C(O)C2O)CO)OC(CO)C(O)C1O SNFSYLYCDAVZGP-UHFFFAOYSA-N 0.000 claims description 53
- IEQCXFNWPAHHQR-UHFFFAOYSA-N lacto-N-neotetraose Natural products OCC1OC(OC2C(C(OC3C(OC(O)C(O)C3O)CO)OC(CO)C2O)O)C(NC(=O)C)C(O)C1OC1OC(CO)C(O)C(O)C1O IEQCXFNWPAHHQR-UHFFFAOYSA-N 0.000 claims description 51
- 229940062780 lacto-n-neotetraose Drugs 0.000 claims description 51
- 241000186000 Bifidobacterium Species 0.000 claims description 49
- 206010033307 Overweight Diseases 0.000 claims description 49
- 208000030159 metabolic disease Diseases 0.000 claims description 48
- 201000010099 disease Diseases 0.000 claims description 47
- AXQLFFDZXPOFPO-UHFFFAOYSA-N UNPD216 Natural products O1C(CO)C(O)C(OC2C(C(O)C(O)C(CO)O2)O)C(NC(=O)C)C1OC(C1O)C(O)C(CO)OC1OC1C(O)C(O)C(O)OC1CO AXQLFFDZXPOFPO-UHFFFAOYSA-N 0.000 claims description 38
- AXQLFFDZXPOFPO-UNTPKZLMSA-N beta-D-Galp-(1->3)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-beta-D-Glcp Chemical compound O([C@@H]1O[C@H](CO)[C@H](O)[C@@H]([C@H]1O)O[C@H]1[C@@H]([C@H]([C@H](O)[C@@H](CO)O1)O[C@H]1[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O1)O)NC(=O)C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)O[C@@H]1CO AXQLFFDZXPOFPO-UNTPKZLMSA-N 0.000 claims description 38
- USIPEGYTBGEPJN-UHFFFAOYSA-N lacto-N-tetraose Natural products O1C(CO)C(O)C(OC2C(C(O)C(O)C(CO)O2)O)C(NC(=O)C)C1OC1C(O)C(CO)OC(OC(C(O)CO)C(O)C(O)C=O)C1O USIPEGYTBGEPJN-UHFFFAOYSA-N 0.000 claims description 38
- 235000016709 nutrition Nutrition 0.000 claims description 37
- 230000001575 pathological effect Effects 0.000 claims description 35
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 33
- 230000007935 neutral effect Effects 0.000 claims description 25
- 241000186018 Bifidobacterium adolescentis Species 0.000 claims description 23
- WJPIUUDKRHCAEL-UHFFFAOYSA-N 3FL Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(C(O)C(O)C(CO)O2)O)C(CO)OC(O)C1O WJPIUUDKRHCAEL-UHFFFAOYSA-N 0.000 claims description 21
- LKOHREGGXUJGKC-UHFFFAOYSA-N Lactodifucotetraose Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(C(O)C(O)OC2CO)OC2C(C(O)C(O)C(C)O2)O)OC(CO)C(O)C1O LKOHREGGXUJGKC-UHFFFAOYSA-N 0.000 claims description 19
- LKOHREGGXUJGKC-GXSKDVPZSA-N alpha-L-Fucp-(1->3)-[alpha-L-Fucp-(1->2)-beta-D-Galp-(1->4)]-beta-D-Glcp Chemical compound C[C@@H]1O[C@@H](O[C@@H]2[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]2O[C@@H]2[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]2O[C@@H]2O[C@@H](C)[C@@H](O)[C@@H](O)[C@@H]2O)[C@@H](O)[C@H](O)[C@@H]1O LKOHREGGXUJGKC-GXSKDVPZSA-N 0.000 claims description 19
- AUNPEJDACLEKSC-ZAYDSPBTSA-N 3-fucosyllactose Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@H](OC(O)[C@H](O)[C@H]2O)CO)O[C@H](CO)[C@@H]1O AUNPEJDACLEKSC-ZAYDSPBTSA-N 0.000 claims description 18
- 238000011161 development Methods 0.000 claims description 18
- FZIVHOUANIQOMU-YIHIYSSUSA-N alpha-L-Fucp-(1->2)-beta-D-Galp-(1->3)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-D-Glcp Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@H]([C@H](O[C@@H]3[C@H]([C@H](O[C@@H]4[C@H](OC(O)[C@H](O)[C@H]4O)CO)O[C@H](CO)[C@@H]3O)O)O[C@H](CO)[C@H]2O)NC(C)=O)O[C@H](CO)[C@H](O)[C@@H]1O FZIVHOUANIQOMU-YIHIYSSUSA-N 0.000 claims description 16
- FZIVHOUANIQOMU-UHFFFAOYSA-N lacto-N-fucopentaose I Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(C(OC3C(C(OC4C(OC(O)C(O)C4O)CO)OC(CO)C3O)O)OC(CO)C2O)NC(C)=O)OC(CO)C(O)C1O FZIVHOUANIQOMU-UHFFFAOYSA-N 0.000 claims description 16
- DVGKRPYUFRZAQW-UHFFFAOYSA-N 3 prime Natural products CC(=O)NC1OC(CC(O)C1C(O)C(O)CO)(OC2C(O)C(CO)OC(OC3C(O)C(O)C(O)OC3CO)C2O)C(=O)O DVGKRPYUFRZAQW-UHFFFAOYSA-N 0.000 claims description 12
- TYALNJQZQRNQNQ-JLYOMPFMSA-N alpha-Neup5Ac-(2->6)-beta-D-Galp-(1->4)-beta-D-Glcp Chemical compound O1[C@@H]([C@H](O)[C@H](O)CO)[C@H](NC(=O)C)[C@@H](O)C[C@@]1(C(O)=O)OC[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)O[C@@H]2CO)O)O1 TYALNJQZQRNQNQ-JLYOMPFMSA-N 0.000 claims description 12
- 241001134772 Bifidobacterium pseudocatenulatum Species 0.000 claims description 11
- 206010018429 Glucose tolerance impaired Diseases 0.000 claims description 11
- 201000009104 prediabetes syndrome Diseases 0.000 claims description 11
- 206010019280 Heart failures Diseases 0.000 claims description 10
- 208000001280 Prediabetic State Diseases 0.000 claims description 10
- OIZGSVFYNBZVIK-FHHHURIISA-N 3'-sialyllactose Chemical compound O1[C@@H]([C@H](O)[C@H](O)CO)[C@H](NC(=O)C)[C@@H](O)C[C@@]1(C(O)=O)O[C@@H]1[C@@H](O)[C@H](O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O)O[C@H](CO)[C@@H]1O OIZGSVFYNBZVIK-FHHHURIISA-N 0.000 claims description 9
- 208000006011 Stroke Diseases 0.000 claims description 7
- 239000002552 dosage form Substances 0.000 claims description 7
- 208000010125 myocardial infarction Diseases 0.000 claims description 6
- 208000030613 peripheral artery disease Diseases 0.000 claims description 5
- TYALNJQZQRNQNQ-UHFFFAOYSA-N #alpha;2,6-sialyllactose Natural products O1C(C(O)C(O)CO)C(NC(=O)C)C(O)CC1(C(O)=O)OCC1C(O)C(O)C(O)C(OC2C(C(O)C(O)OC2CO)O)O1 TYALNJQZQRNQNQ-UHFFFAOYSA-N 0.000 claims description 3
- CILYIEBUXJIHCO-UHFFFAOYSA-N 102778-91-6 Natural products O1C(C(O)C(O)CO)C(NC(=O)C)C(O)CC1(C(O)=O)OC1C(O)C(OC2C(C(O)C(O)OC2CO)O)OC(CO)C1O CILYIEBUXJIHCO-UHFFFAOYSA-N 0.000 claims description 3
- 229940062827 2'-fucosyllactose Drugs 0.000 claims description 3
- HWHQUWQCBPAQQH-UHFFFAOYSA-N 2-O-alpha-L-Fucosyl-lactose Natural products OC1C(O)C(O)C(C)OC1OC1C(O)C(O)C(CO)OC1OC(C(O)CO)C(O)C(O)C=O HWHQUWQCBPAQQH-UHFFFAOYSA-N 0.000 claims description 3
- CILYIEBUXJIHCO-UITFWXMXSA-N N-acetyl-alpha-neuraminyl-(2->3)-beta-D-galactosyl-(1->4)-beta-D-glucose Chemical compound O1[C@@H]([C@H](O)[C@H](O)CO)[C@H](NC(=O)C)[C@@H](O)C[C@@]1(C(O)=O)O[C@@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)O[C@@H]2CO)O)O[C@H](CO)[C@@H]1O CILYIEBUXJIHCO-UITFWXMXSA-N 0.000 claims description 3
- OIZGSVFYNBZVIK-UHFFFAOYSA-N N-acetylneuraminosyl-D-lactose Natural products O1C(C(O)C(O)CO)C(NC(=O)C)C(O)CC1(C(O)=O)OC1C(O)C(OC(C(O)CO)C(O)C(O)C=O)OC(CO)C1O OIZGSVFYNBZVIK-UHFFFAOYSA-N 0.000 claims description 3
- 208000010496 Heart Arrest Diseases 0.000 claims description 2
- 208000010378 Pulmonary Embolism Diseases 0.000 claims description 2
- 238000000034 method Methods 0.000 abstract description 42
- 241000282412 Homo Species 0.000 abstract description 10
- 210000004369 blood Anatomy 0.000 description 47
- 239000008280 blood Substances 0.000 description 47
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 40
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 40
- 239000008103 glucose Substances 0.000 description 38
- 241000699670 Mus sp. Species 0.000 description 33
- 150000001720 carbohydrates Chemical class 0.000 description 30
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 30
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 29
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 28
- 235000014633 carbohydrates Nutrition 0.000 description 26
- 244000005709 gut microbiome Species 0.000 description 25
- 239000008194 pharmaceutical composition Substances 0.000 description 24
- 239000000047 product Substances 0.000 description 24
- 108020004414 DNA Proteins 0.000 description 22
- 206010012601 diabetes mellitus Diseases 0.000 description 22
- 241000736262 Microbiota Species 0.000 description 20
- 235000005911 diet Nutrition 0.000 description 19
- 235000013305 food Nutrition 0.000 description 19
- 210000002216 heart Anatomy 0.000 description 19
- 230000037213 diet Effects 0.000 description 18
- 239000003814 drug Substances 0.000 description 17
- 239000003826 tablet Substances 0.000 description 17
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 16
- 102400000322 Glucagon-like peptide 1 Human genes 0.000 description 16
- 101800000224 Glucagon-like peptide 1 Proteins 0.000 description 16
- 108090000623 proteins and genes Proteins 0.000 description 16
- 239000000243 solution Substances 0.000 description 16
- 102000004877 Insulin Human genes 0.000 description 15
- 108090001061 Insulin Proteins 0.000 description 15
- 229940125396 insulin Drugs 0.000 description 15
- 238000004458 analytical method Methods 0.000 description 14
- 230000037396 body weight Effects 0.000 description 14
- 229940079593 drug Drugs 0.000 description 14
- 230000037406 food intake Effects 0.000 description 14
- 150000002632 lipids Chemical class 0.000 description 14
- 239000007788 liquid Substances 0.000 description 14
- 210000000577 adipose tissue Anatomy 0.000 description 13
- 235000012000 cholesterol Nutrition 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- 239000002158 endotoxin Substances 0.000 description 13
- 239000000499 gel Substances 0.000 description 13
- 210000001519 tissue Anatomy 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 239000003925 fat Substances 0.000 description 12
- 229920006008 lipopolysaccharide Polymers 0.000 description 12
- 238000004519 manufacturing process Methods 0.000 description 12
- 235000018102 proteins Nutrition 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 12
- 108020004465 16S ribosomal RNA Proteins 0.000 description 11
- -1 LNFP-II Chemical compound 0.000 description 11
- 239000003921 oil Substances 0.000 description 11
- 235000019198 oils Nutrition 0.000 description 11
- 239000000843 powder Substances 0.000 description 11
- 239000006041 probiotic Substances 0.000 description 11
- 235000018291 probiotics Nutrition 0.000 description 11
- 241000894006 Bacteria Species 0.000 description 10
- 206010020772 Hypertension Diseases 0.000 description 10
- RQNFGIWYOACERD-OCQMRBNYSA-N alpha-L-Fucp-(1->4)-[alpha-L-Fucp-(1->2)-beta-D-Galp-(1->3)]-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-D-Glcp Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@@H](CO)O[C@@H](O[C@@H]3[C@H]([C@H](O[C@@H]4[C@H](OC(O)[C@H](O)[C@H]4O)CO)O[C@H](CO)[C@@H]3O)O)[C@@H]2NC(C)=O)O[C@H]2[C@H]([C@H](O)[C@H](O)[C@H](C)O2)O)O[C@H](CO)[C@H](O)[C@@H]1O RQNFGIWYOACERD-OCQMRBNYSA-N 0.000 description 10
- 230000036772 blood pressure Effects 0.000 description 10
- 239000003795 chemical substances by application Substances 0.000 description 10
- 239000000839 emulsion Substances 0.000 description 10
- 230000000968 intestinal effect Effects 0.000 description 10
- RQNFGIWYOACERD-UHFFFAOYSA-N lacto-N-Difucosylhexaose I Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(C(CO)OC(OC3C(C(OC4C(OC(O)C(O)C4O)CO)OC(CO)C3O)O)C2NC(C)=O)OC2C(C(O)C(O)C(C)O2)O)OC(CO)C(O)C1O RQNFGIWYOACERD-UHFFFAOYSA-N 0.000 description 10
- OQIUPKPUOLIHHS-UHFFFAOYSA-N lacto-N-difucohexaose I Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(C(CO)OC(OC3C(C(OC(C(O)CO)C(O)C(O)C=O)OC(CO)C3O)O)C2NC(C)=O)OC2C(C(O)C(O)C(C)O2)O)OC(CO)C(O)C1O OQIUPKPUOLIHHS-UHFFFAOYSA-N 0.000 description 10
- 239000000314 lubricant Substances 0.000 description 10
- 230000000813 microbial effect Effects 0.000 description 10
- 239000002953 phosphate buffered saline Substances 0.000 description 10
- 230000002829 reductive effect Effects 0.000 description 10
- 241000894007 species Species 0.000 description 10
- 102400000326 Glucagon-like peptide 2 Human genes 0.000 description 9
- 101800000221 Glucagon-like peptide 2 Proteins 0.000 description 9
- 206010061218 Inflammation Diseases 0.000 description 9
- 230000009286 beneficial effect Effects 0.000 description 9
- 239000011230 binding agent Substances 0.000 description 9
- 210000004204 blood vessel Anatomy 0.000 description 9
- 150000001875 compounds Chemical group 0.000 description 9
- 239000003398 denaturant Substances 0.000 description 9
- 238000003935 denaturing gradient gel electrophoresis Methods 0.000 description 9
- 235000012631 food intake Nutrition 0.000 description 9
- TWSALRJGPBVBQU-PKQQPRCHSA-N glucagon-like peptide 2 Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O)[C@@H](C)CC)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=CC=C1 TWSALRJGPBVBQU-PKQQPRCHSA-N 0.000 description 9
- 230000004054 inflammatory process Effects 0.000 description 9
- 230000003870 intestinal permeability Effects 0.000 description 9
- 230000002503 metabolic effect Effects 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 9
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 8
- TVVLIFCVJJSLBL-SEHWTJTBSA-N Lacto-N-fucopentaose V Chemical compound O[C@H]1C(O)C(O)[C@H](C)O[C@H]1OC([C@@H](O)C=O)[C@@H](C(O)CO)O[C@H]1[C@H](O)[C@@H](OC2[C@@H](C(OC3[C@@H](C(O)C(O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](O)[C@@H](CO)O1 TVVLIFCVJJSLBL-SEHWTJTBSA-N 0.000 description 8
- PDWGIAAFQACISG-QZBWVFMZSA-N beta-D-Gal-(1->3)-beta-D-GlcNAc-(1->3)-[beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->6)]-beta-D-Gal-(1->4)-D-Glc Chemical compound O([C@H]1[C@H](O)[C@H]([C@@H](O[C@@H]1CO)OC[C@@H]1[C@@H]([C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](O)[C@H](O[C@@H]2[C@H](OC(O)[C@H](O)[C@H]2O)CO)O1)O)NC(=O)C)[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O PDWGIAAFQACISG-QZBWVFMZSA-N 0.000 description 8
- NPPRJALWPIXIHO-PNCMPRLYSA-N beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->3)-[beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->6)]-beta-D-Gal-(1->4)-D-Glc Chemical compound O([C@H]1[C@H](O)[C@H]([C@@H](O[C@@H]1CO)OC[C@@H]1[C@@H]([C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O[C@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)[C@@H](CO)O2)NC(C)=O)[C@@H](O)[C@H](O[C@@H]2[C@H](OC(O)[C@H](O)[C@H]2O)CO)O1)O)NC(=O)C)[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O NPPRJALWPIXIHO-PNCMPRLYSA-N 0.000 description 8
- DMYPRRDPOMGEAK-XWDFSUOISA-N beta-D-Galp-(1->3)-[alpha-L-Fucp-(1->4)]-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-D-Glcp Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@H]4[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O4)O)[C@H](O[C@H]4[C@H]([C@H](O)[C@H](O)[C@H](C)O4)O)[C@@H](CO)O3)NC(C)=O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](CO)OC(O)[C@@H]1O DMYPRRDPOMGEAK-XWDFSUOISA-N 0.000 description 8
- 239000002775 capsule Substances 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 235000019197 fats Nutrition 0.000 description 8
- 230000036541 health Effects 0.000 description 8
- DMYPRRDPOMGEAK-UHFFFAOYSA-N lacto-N-difucohexaose II Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(C(OC3C(C(OC4C(C(O)C(O)C(CO)O4)O)C(OC4C(C(O)C(O)C(C)O4)O)C(CO)O3)NC(C)=O)C(O)C(CO)O2)O)C(CO)OC(O)C1O DMYPRRDPOMGEAK-UHFFFAOYSA-N 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 239000000546 pharmaceutical excipient Substances 0.000 description 8
- 229920002401 polyacrylamide Polymers 0.000 description 8
- 235000021391 short chain fatty acids Nutrition 0.000 description 8
- 239000006188 syrup Substances 0.000 description 8
- 235000020357 syrup Nutrition 0.000 description 8
- 241001608472 Bifidobacterium longum Species 0.000 description 7
- 102000004127 Cytokines Human genes 0.000 description 7
- 108090000695 Cytokines Proteins 0.000 description 7
- 230000002411 adverse Effects 0.000 description 7
- 239000000090 biomarker Substances 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 238000013270 controlled release Methods 0.000 description 7
- 239000000796 flavoring agent Substances 0.000 description 7
- 210000000936 intestine Anatomy 0.000 description 7
- 238000012423 maintenance Methods 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 210000003462 vein Anatomy 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 108020000946 Bacterial DNA Proteins 0.000 description 6
- 238000003304 gavage Methods 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 6
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 6
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 6
- 230000002757 inflammatory effect Effects 0.000 description 6
- 229910052740 iodine Inorganic materials 0.000 description 6
- 235000020978 long-chain polyunsaturated fatty acids Nutrition 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- ZDZMLVPSYYRJNI-CYQYEHMMSA-N p-lacto-n-hexaose Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1N=C(C)O)O[C@@H]1[C@@H](O)[C@H](O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O)OC([C@@H]1O)CO[C@H]1[C@@H]([C@H](C(O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](CO)O1)O)N=C(O)C)[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O ZDZMLVPSYYRJNI-CYQYEHMMSA-N 0.000 description 6
- 229940068196 placebo Drugs 0.000 description 6
- 239000000902 placebo Substances 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 150000004666 short chain fatty acids Chemical class 0.000 description 6
- 229910021642 ultra pure water Inorganic materials 0.000 description 6
- 239000012498 ultrapure water Substances 0.000 description 6
- 229940088594 vitamin Drugs 0.000 description 6
- 229930003231 vitamin Natural products 0.000 description 6
- 235000013343 vitamin Nutrition 0.000 description 6
- 239000011782 vitamin Substances 0.000 description 6
- 108010000231 Choloylglycine hydrolase Proteins 0.000 description 5
- 108010023302 HDL Cholesterol Proteins 0.000 description 5
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 210000001367 artery Anatomy 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 5
- 230000033228 biological regulation Effects 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 235000008504 concentrate Nutrition 0.000 description 5
- 239000012141 concentrate Substances 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- 239000002934 diuretic Substances 0.000 description 5
- 229940030606 diuretics Drugs 0.000 description 5
- 238000009547 dual-energy X-ray absorptiometry Methods 0.000 description 5
- 235000013399 edible fruits Nutrition 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 239000003629 gastrointestinal hormone Substances 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 5
- 229910052500 inorganic mineral Inorganic materials 0.000 description 5
- WMYQZGAEYLPOSX-JOEMMLBASA-N lex-lactose Chemical compound OC1[C@@H](O)[C@@H](O)[C@@H](C)O[C@@H]1O[C@H]1C(O[C@H]2[C@@H](C(O)C(O)C(CO)O2)O)[C@@H](CO)O[C@@H](O[C@@H]2[C@H]([C@H](OC(C(O)CO)[C@H](O)[C@@H](O)C=O)OC(CO)C2O)O)C1NC(C)=O WMYQZGAEYLPOSX-JOEMMLBASA-N 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 235000021073 macronutrients Nutrition 0.000 description 5
- 239000002207 metabolite Substances 0.000 description 5
- 244000005700 microbiome Species 0.000 description 5
- 239000008108 microcrystalline cellulose Substances 0.000 description 5
- 229940016286 microcrystalline cellulose Drugs 0.000 description 5
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 5
- 235000010755 mineral Nutrition 0.000 description 5
- 239000011707 mineral Substances 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 description 5
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 229920002498 Beta-glucan Polymers 0.000 description 4
- 241000186016 Bifidobacterium bifidum Species 0.000 description 4
- YNXLOPYTAAFMTN-SBUIBGKBSA-N C([C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)C1=CC=C(O)C=C1 Chemical compound C([C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)C1=CC=C(O)C=C1 YNXLOPYTAAFMTN-SBUIBGKBSA-N 0.000 description 4
- 241000192125 Firmicutes Species 0.000 description 4
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 4
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 description 4
- 108010088847 Peptide YY Proteins 0.000 description 4
- 102100029909 Peptide YY Human genes 0.000 description 4
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 108010046377 Whey Proteins Proteins 0.000 description 4
- 102000007544 Whey Proteins Human genes 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 4
- 229940024606 amino acid Drugs 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 235000019789 appetite Nutrition 0.000 description 4
- 230000036528 appetite Effects 0.000 description 4
- 230000004888 barrier function Effects 0.000 description 4
- 235000013734 beta-carotene Nutrition 0.000 description 4
- 239000011648 beta-carotene Substances 0.000 description 4
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 4
- 229960002747 betacarotene Drugs 0.000 description 4
- 229940002008 bifidobacterium bifidum Drugs 0.000 description 4
- 229940009291 bifidobacterium longum Drugs 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 235000010418 carrageenan Nutrition 0.000 description 4
- 229920001525 carrageenan Polymers 0.000 description 4
- 239000000679 carrageenan Substances 0.000 description 4
- 229940113118 carrageenan Drugs 0.000 description 4
- 208000029078 coronary artery disease Diseases 0.000 description 4
- 230000000875 corresponding effect Effects 0.000 description 4
- 230000003111 delayed effect Effects 0.000 description 4
- 239000012527 feed solution Substances 0.000 description 4
- 238000000855 fermentation Methods 0.000 description 4
- 230000004151 fermentation Effects 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 4
- 235000013355 food flavoring agent Nutrition 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 235000009200 high fat diet Nutrition 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 239000003906 humectant Substances 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 239000003701 inert diluent Substances 0.000 description 4
- 238000011283 initial treatment period Methods 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 235000012680 lutein Nutrition 0.000 description 4
- 229960005375 lutein Drugs 0.000 description 4
- 239000001656 lutein Substances 0.000 description 4
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 description 4
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 description 4
- 235000012661 lycopene Nutrition 0.000 description 4
- 229960004999 lycopene Drugs 0.000 description 4
- 239000001751 lycopene Substances 0.000 description 4
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 description 4
- 210000001165 lymph node Anatomy 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 235000013336 milk Nutrition 0.000 description 4
- 239000008267 milk Substances 0.000 description 4
- 210000004080 milk Anatomy 0.000 description 4
- 210000004165 myocardium Anatomy 0.000 description 4
- 230000035764 nutrition Effects 0.000 description 4
- 239000006072 paste Substances 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 230000035699 permeability Effects 0.000 description 4
- 239000011591 potassium Substances 0.000 description 4
- 229960003975 potassium Drugs 0.000 description 4
- 229910052700 potassium Inorganic materials 0.000 description 4
- 230000000529 probiotic effect Effects 0.000 description 4
- 235000021251 pulses Nutrition 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000002002 slurry Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 230000002459 sustained effect Effects 0.000 description 4
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 4
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 description 4
- 239000003656 tris buffered saline Substances 0.000 description 4
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 description 4
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 4
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 4
- 239000005541 ACE inhibitor Substances 0.000 description 3
- 244000215068 Acacia senegal Species 0.000 description 3
- 108091093088 Amplicon Proteins 0.000 description 3
- 206010002383 Angina Pectoris Diseases 0.000 description 3
- 206010070545 Bacterial translocation Diseases 0.000 description 3
- 241000605059 Bacteroidetes Species 0.000 description 3
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 description 3
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 3
- 241000252983 Caecum Species 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 229940127291 Calcium channel antagonist Drugs 0.000 description 3
- 108010076119 Caseins Proteins 0.000 description 3
- 206010008479 Chest Pain Diseases 0.000 description 3
- 229920002307 Dextran Polymers 0.000 description 3
- 208000000059 Dyspnea Diseases 0.000 description 3
- 206010013975 Dyspnoeas Diseases 0.000 description 3
- 208000037487 Endotoxemia Diseases 0.000 description 3
- 229920000084 Gum arabic Polymers 0.000 description 3
- 101150026536 HDA2 gene Proteins 0.000 description 3
- 108010010234 HDL Lipoproteins Proteins 0.000 description 3
- 102000015779 HDL Lipoproteins Human genes 0.000 description 3
- 108091027305 Heteroduplex Proteins 0.000 description 3
- 229920001202 Inulin Polymers 0.000 description 3
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 3
- 108010028554 LDL Cholesterol Proteins 0.000 description 3
- 241000186604 Lactobacillus reuteri Species 0.000 description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
- 229920002774 Maltodextrin Polymers 0.000 description 3
- 208000001145 Metabolic Syndrome Diseases 0.000 description 3
- 102000014171 Milk Proteins Human genes 0.000 description 3
- 108010011756 Milk Proteins Proteins 0.000 description 3
- 102000003940 Occludin Human genes 0.000 description 3
- 108090000304 Occludin Proteins 0.000 description 3
- 240000007594 Oryza sativa Species 0.000 description 3
- 235000007164 Oryza sativa Nutrition 0.000 description 3
- 108010084695 Pea Proteins Proteins 0.000 description 3
- 108010009736 Protein Hydrolysates Proteins 0.000 description 3
- 235000019485 Safflower oil Nutrition 0.000 description 3
- 108010073771 Soybean Proteins Proteins 0.000 description 3
- 208000007536 Thrombosis Diseases 0.000 description 3
- 240000008042 Zea mays Species 0.000 description 3
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 3
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 3
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 3
- 235000010489 acacia gum Nutrition 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 238000000246 agarose gel electrophoresis Methods 0.000 description 3
- 230000000172 allergic effect Effects 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 229940035676 analgesics Drugs 0.000 description 3
- 239000002333 angiotensin II receptor antagonist Substances 0.000 description 3
- 229940125364 angiotensin receptor blocker Drugs 0.000 description 3
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 3
- 238000000137 annealing Methods 0.000 description 3
- 239000000730 antalgic agent Substances 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 239000002260 anti-inflammatory agent Substances 0.000 description 3
- 229940121363 anti-inflammatory agent Drugs 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 208000010668 atopic eczema Diseases 0.000 description 3
- 230000007375 bacterial translocation Effects 0.000 description 3
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 239000000480 calcium channel blocker Substances 0.000 description 3
- 239000004202 carbamide Substances 0.000 description 3
- 235000021466 carotenoid Nutrition 0.000 description 3
- 150000001747 carotenoids Chemical class 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 210000004534 cecum Anatomy 0.000 description 3
- 235000013339 cereals Nutrition 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 239000003240 coconut oil Substances 0.000 description 3
- 235000019864 coconut oil Nutrition 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 235000005822 corn Nutrition 0.000 description 3
- 230000002596 correlated effect Effects 0.000 description 3
- 230000009089 cytolysis Effects 0.000 description 3
- 238000004925 denaturation Methods 0.000 description 3
- 230000036425 denaturation Effects 0.000 description 3
- 238000007865 diluting Methods 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 239000002270 dispersing agent Substances 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 235000006694 eating habits Nutrition 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 201000010063 epididymitis Diseases 0.000 description 3
- JUKPWJGBANNWMW-VWBFHTRKSA-N eplerenone Chemical compound C([C@@H]1[C@]2(C)C[C@H]3O[C@]33[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)C(=O)OC)C[C@@]21CCC(=O)O1 JUKPWJGBANNWMW-VWBFHTRKSA-N 0.000 description 3
- 230000005284 excitation Effects 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 230000002641 glycemic effect Effects 0.000 description 3
- 239000011544 gradient gel Substances 0.000 description 3
- 239000003979 granulating agent Substances 0.000 description 3
- 208000019622 heart disease Diseases 0.000 description 3
- 238000012165 high-throughput sequencing Methods 0.000 description 3
- 230000001524 infective effect Effects 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 238000011221 initial treatment Methods 0.000 description 3
- 230000000297 inotrophic effect Effects 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 3
- 229940029339 inulin Drugs 0.000 description 3
- 210000001630 jejunum Anatomy 0.000 description 3
- 229960003299 ketamine Drugs 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- 235000021239 milk protein Nutrition 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 3
- 238000007410 oral glucose tolerance test Methods 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 210000003200 peritoneal cavity Anatomy 0.000 description 3
- 229920005862 polyol Polymers 0.000 description 3
- 150000003077 polyols Chemical class 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 235000013406 prebiotics Nutrition 0.000 description 3
- 239000003531 protein hydrolysate Substances 0.000 description 3
- 230000002294 pubertal effect Effects 0.000 description 3
- 229940100618 rectal suppository Drugs 0.000 description 3
- 239000006215 rectal suppository Substances 0.000 description 3
- 230000000717 retained effect Effects 0.000 description 3
- 230000033764 rhythmic process Effects 0.000 description 3
- 235000009566 rice Nutrition 0.000 description 3
- 235000005713 safflower oil Nutrition 0.000 description 3
- 239000003813 safflower oil Substances 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 208000013220 shortness of breath Diseases 0.000 description 3
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 229940001941 soy protein Drugs 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 230000009469 supplementation Effects 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 229940124549 vasodilator Drugs 0.000 description 3
- 239000003071 vasodilator agent Substances 0.000 description 3
- 235000013311 vegetables Nutrition 0.000 description 3
- 230000009278 visceral effect Effects 0.000 description 3
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 3
- 229960005080 warfarin Drugs 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- 235000021119 whey protein Nutrition 0.000 description 3
- 229920001285 xanthan gum Polymers 0.000 description 3
- 235000010493 xanthan gum Nutrition 0.000 description 3
- 239000000230 xanthan gum Substances 0.000 description 3
- 229940082509 xanthan gum Drugs 0.000 description 3
- 229960001600 xylazine Drugs 0.000 description 3
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N 2,3,4,5-tetrahydroxypentanal Chemical compound OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 2
- PVXPPJIGRGXGCY-TZLCEDOOSA-N 6-O-alpha-D-glucopyranosyl-D-fructofuranose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)C(O)(CO)O1 PVXPPJIGRGXGCY-TZLCEDOOSA-N 0.000 description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 2
- 235000006491 Acacia senegal Nutrition 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 2
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 244000247812 Amorphophallus rivieri Species 0.000 description 2
- 235000001206 Amorphophallus rivieri Nutrition 0.000 description 2
- 229920000189 Arabinogalactan Polymers 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 102000011632 Caseins Human genes 0.000 description 2
- 229920001661 Chitosan Polymers 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 2
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 2
- 241001143779 Dorea Species 0.000 description 2
- 208000032928 Dyslipidaemia Diseases 0.000 description 2
- 238000011891 EIA kit Methods 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- 108010024636 Glutathione Proteins 0.000 description 2
- 229920002907 Guar gum Polymers 0.000 description 2
- 229920000569 Gum karaya Polymers 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 108090000174 Interleukin-10 Proteins 0.000 description 2
- 102000003814 Interleukin-10 Human genes 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 229920002752 Konjac Polymers 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 201000010538 Lactose Intolerance Diseases 0.000 description 2
- 229920000161 Locust bean gum Polymers 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 239000005913 Maltodextrin Substances 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- 102000014962 Monocyte Chemoattractant Proteins Human genes 0.000 description 2
- 108010064136 Monocyte Chemoattractant Proteins Proteins 0.000 description 2
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 208000007683 Pediatric Obesity Diseases 0.000 description 2
- 244000134552 Plantago ovata Species 0.000 description 2
- 235000003421 Plantago ovata Nutrition 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 2
- 239000009223 Psyllium Substances 0.000 description 2
- 229920000294 Resistant starch Polymers 0.000 description 2
- VYGQUTWHTHXGQB-FFHKNEKCSA-N Retinol Palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 241000934878 Sterculia Species 0.000 description 2
- 235000019486 Sunflower oil Nutrition 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- 102000018594 Tumour necrosis factor Human genes 0.000 description 2
- 108050007852 Tumour necrosis factor Proteins 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 229960002478 aldosterone Drugs 0.000 description 2
- 229940072056 alginate Drugs 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 239000003443 antiviral agent Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 235000019312 arabinogalactan Nutrition 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 239000002876 beta blocker Substances 0.000 description 2
- 229940097320 beta blocking agent Drugs 0.000 description 2
- 239000003613 bile acid Substances 0.000 description 2
- 239000003833 bile salt Substances 0.000 description 2
- 229940093761 bile salts Drugs 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 239000000828 canola oil Substances 0.000 description 2
- 235000019519 canola oil Nutrition 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
- 235000021240 caseins Nutrition 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 239000000562 conjugate Substances 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 235000020940 control diet Nutrition 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 2
- 229960005156 digoxin Drugs 0.000 description 2
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 229960001208 eplerenone Drugs 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 235000013312 flour Nutrition 0.000 description 2
- 229960000304 folic acid Drugs 0.000 description 2
- 235000019152 folic acid Nutrition 0.000 description 2
- 239000011724 folic acid Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- 235000003969 glutathione Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 235000010417 guar gum Nutrition 0.000 description 2
- 239000000665 guar gum Substances 0.000 description 2
- 229960002154 guar gum Drugs 0.000 description 2
- 230000009931 harmful effect Effects 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 230000003914 insulin secretion Effects 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 210000001596 intra-abdominal fat Anatomy 0.000 description 2
- 235000010494 karaya gum Nutrition 0.000 description 2
- 239000000231 karaya gum Substances 0.000 description 2
- 229940039371 karaya gum Drugs 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000000252 konjac Substances 0.000 description 2
- 235000010485 konjac Nutrition 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 150000002597 lactoses Chemical class 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 235000010420 locust bean gum Nutrition 0.000 description 2
- 239000000711 locust bean gum Substances 0.000 description 2
- 229940057948 magnesium stearate Drugs 0.000 description 2
- 229940035034 maltodextrin Drugs 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 229940057917 medium chain triglycerides Drugs 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 235000019895 oat fiber Nutrition 0.000 description 2
- 238000013116 obese mouse model Methods 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 235000019702 pea protein Nutrition 0.000 description 2
- 235000010987 pectin Nutrition 0.000 description 2
- 229920001277 pectin Polymers 0.000 description 2
- 239000001814 pectin Substances 0.000 description 2
- 229960000292 pectin Drugs 0.000 description 2
- 229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 2
- 150000008442 polyphenolic compounds Chemical class 0.000 description 2
- 235000013824 polyphenols Nutrition 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 230000008092 positive effect Effects 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000009862 primary prevention Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 229960002429 proline Drugs 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 229940070687 psyllium Drugs 0.000 description 2
- 210000003314 quadriceps muscle Anatomy 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 235000021254 resistant starch Nutrition 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 210000003705 ribosome Anatomy 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 230000009863 secondary prevention Effects 0.000 description 2
- 239000011669 selenium Substances 0.000 description 2
- 229910052711 selenium Inorganic materials 0.000 description 2
- 235000011649 selenium Nutrition 0.000 description 2
- 229940091258 selenium supplement Drugs 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 235000019615 sensations Nutrition 0.000 description 2
- 229960001153 serine Drugs 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 235000010413 sodium alginate Nutrition 0.000 description 2
- 239000000661 sodium alginate Substances 0.000 description 2
- 229940005550 sodium alginate Drugs 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 150000005846 sugar alcohols Chemical class 0.000 description 2
- 239000002600 sunflower oil Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 229960003080 taurine Drugs 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 229960002898 threonine Drugs 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 235000019155 vitamin A Nutrition 0.000 description 2
- 239000011719 vitamin A Substances 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- 235000020985 whole grains Nutrition 0.000 description 2
- 235000013618 yogurt Nutrition 0.000 description 2
- LUEWUZLMQUOBSB-FSKGGBMCSA-N (2s,3s,4s,5s,6r)-2-[(2r,3s,4r,5r,6s)-6-[(2r,3s,4r,5s,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5s,6r)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](OC3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-FSKGGBMCSA-N 0.000 description 1
- JKQXZKUSFCKOGQ-JLGXGRJMSA-N (3R,3'R)-beta,beta-carotene-3,3'-diol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-JLGXGRJMSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 description 1
- PMYDPQQPEAYXKD-UHFFFAOYSA-N 3-hydroxy-n-naphthalen-2-ylnaphthalene-2-carboxamide Chemical compound C1=CC=CC2=CC(NC(=O)C3=CC4=CC=CC=C4C=C3O)=CC=C21 PMYDPQQPEAYXKD-UHFFFAOYSA-N 0.000 description 1
- HFDKKNHCYWNNNQ-YOGANYHLSA-N 75976-10-2 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)N)C(C)C)[C@@H](C)O)C1=CC=C(O)C=C1 HFDKKNHCYWNNNQ-YOGANYHLSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010000117 Abnormal behaviour Diseases 0.000 description 1
- 241001156739 Actinobacteria <phylum> Species 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 208000004476 Acute Coronary Syndrome Diseases 0.000 description 1
- 206010048998 Acute phase reaction Diseases 0.000 description 1
- 102000011690 Adiponectin Human genes 0.000 description 1
- 108010076365 Adiponectin Proteins 0.000 description 1
- 241000701474 Alistipes Species 0.000 description 1
- 241001135230 Alistipes putredinis Species 0.000 description 1
- 102000008873 Angiotensin II receptor Human genes 0.000 description 1
- 108050000824 Angiotensin II receptor Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 208000031729 Bacteremia Diseases 0.000 description 1
- 241000606125 Bacteroides Species 0.000 description 1
- 241000217846 Bacteroides caccae Species 0.000 description 1
- 241000606123 Bacteroides thetaiotaomicron Species 0.000 description 1
- 241000606219 Bacteroides uniformis Species 0.000 description 1
- 241000606215 Bacteroides vulgatus Species 0.000 description 1
- 241000186014 Bifidobacterium angulatum Species 0.000 description 1
- 241000483634 Bifidobacterium animalis subsp. lactis BB-12 Species 0.000 description 1
- 241000186011 Bifidobacterium catenulatum Species 0.000 description 1
- 241001089584 Bifidobacterium kashiwanohense Species 0.000 description 1
- 241001202853 Blautia Species 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000167854 Bourreria succulenta Species 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- 108010074051 C-Reactive Protein Proteins 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 235000019743 Choline chloride Nutrition 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 229910021555 Chromium Chloride Inorganic materials 0.000 description 1
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 1
- 241001464956 Collinsella Species 0.000 description 1
- 241001262170 Collinsella aerofaciens Species 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 241001464948 Coprococcus Species 0.000 description 1
- 244000241257 Cucumis melo Species 0.000 description 1
- 235000015510 Cucumis melo subsp melo Nutrition 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 241000016537 Dorea longicatena Species 0.000 description 1
- 208000027244 Dysbiosis Diseases 0.000 description 1
- 206010014486 Elevated triglycerides Diseases 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 241000186394 Eubacterium Species 0.000 description 1
- 241001137858 Euryarchaeota Species 0.000 description 1
- 241001608234 Faecalibacterium Species 0.000 description 1
- 241000605980 Faecalibacterium prausnitzii Species 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 235000016623 Fragaria vesca Nutrition 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 1
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 1
- 241001453172 Fusobacteria Species 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 229920002148 Gellan gum Polymers 0.000 description 1
- 229920002581 Glucomannan Polymers 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 238000013218 HFD mouse model Methods 0.000 description 1
- 102100025255 Haptoglobin Human genes 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 240000005979 Hordeum vulgare Species 0.000 description 1
- 235000007340 Hordeum vulgare Nutrition 0.000 description 1
- 239000005905 Hydrolysed protein Substances 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 208000015580 Increased body weight Diseases 0.000 description 1
- 102000003746 Insulin Receptor Human genes 0.000 description 1
- 108010001127 Insulin Receptor Proteins 0.000 description 1
- 102000003812 Interleukin-15 Human genes 0.000 description 1
- 108090000172 Interleukin-15 Proteins 0.000 description 1
- 102000003810 Interleukin-18 Human genes 0.000 description 1
- 108090000171 Interleukin-18 Proteins 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 102000004890 Interleukin-8 Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 102000036770 Islet Amyloid Polypeptide Human genes 0.000 description 1
- 108010041872 Islet Amyloid Polypeptide Proteins 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 240000001046 Lactobacillus acidophilus Species 0.000 description 1
- 244000116699 Lactobacillus acidophilus NCFM Species 0.000 description 1
- 240000001929 Lactobacillus brevis Species 0.000 description 1
- 241000093427 Lactobacillus fermentum CECT 5716 Species 0.000 description 1
- 241000218588 Lactobacillus rhamnosus Species 0.000 description 1
- 241000917009 Lactobacillus rhamnosus GG Species 0.000 description 1
- 241000239218 Limulus Species 0.000 description 1
- 102000009571 Macrophage Inflammatory Proteins Human genes 0.000 description 1
- 108010009474 Macrophage Inflammatory Proteins Proteins 0.000 description 1
- 241000220225 Malus Species 0.000 description 1
- 235000011430 Malus pumila Nutrition 0.000 description 1
- 235000015103 Malus silvestris Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000004368 Modified starch Substances 0.000 description 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-RTRLPJTCSA-N N-acetyl-D-glucosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-RTRLPJTCSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 1
- 201000002451 Overnutrition Diseases 0.000 description 1
- 206010033425 Pain in extremity Diseases 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 102000018886 Pancreatic Polypeptide Human genes 0.000 description 1
- 241000204306 Parabacteroides merdae Species 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 241000425347 Phyla <beetle> Species 0.000 description 1
- 229920000148 Polycarbophil calcium Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 241000192142 Proteobacteria Species 0.000 description 1
- 244000141353 Prunus domestica Species 0.000 description 1
- 239000004373 Pullulan Substances 0.000 description 1
- 229920001218 Pullulan Polymers 0.000 description 1
- 235000014443 Pyrus communis Nutrition 0.000 description 1
- 240000001987 Pyrus communis Species 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- VYGQUTWHTHXGQB-UHFFFAOYSA-N Retinol hexadecanoate Natural products CCCCCCCCCCCCCCCC(=O)OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-UHFFFAOYSA-N 0.000 description 1
- 241000605947 Roseburia Species 0.000 description 1
- 241000398180 Roseburia intestinalis Species 0.000 description 1
- 240000007651 Rubus glaucus Species 0.000 description 1
- 235000011034 Rubus glaucus Nutrition 0.000 description 1
- 235000009122 Rubus idaeus Nutrition 0.000 description 1
- 241000192031 Ruminococcus Species 0.000 description 1
- 241000123753 Ruminococcus bromii Species 0.000 description 1
- 241000202356 Ruminococcus lactaris Species 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 101000983124 Sus scrofa Pancreatic prohormone precursor Proteins 0.000 description 1
- 241000390529 Synergistetes Species 0.000 description 1
- 235000009470 Theobroma cacao Nutrition 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 102000000591 Tight Junction Proteins Human genes 0.000 description 1
- 108010002321 Tight Junction Proteins Proteins 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 240000000851 Vaccinium corymbosum Species 0.000 description 1
- 235000003095 Vaccinium corymbosum Nutrition 0.000 description 1
- 235000017537 Vaccinium myrtillus Nutrition 0.000 description 1
- 241001261005 Verrucomicrobia Species 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 235000021068 Western diet Nutrition 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- JKQXZKUSFCKOGQ-LQFQNGICSA-N Z-zeaxanthin Natural products C([C@H](O)CC=1C)C(C)(C)C=1C=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-LQFQNGICSA-N 0.000 description 1
- QOPRSMDTRDMBNK-RNUUUQFGSA-N Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCC(O)C1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C QOPRSMDTRDMBNK-RNUUUQFGSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 102000044820 Zonula Occludens-1 Human genes 0.000 description 1
- 108700007340 Zonula Occludens-1 Proteins 0.000 description 1
- FJJCIZWZNKZHII-UHFFFAOYSA-N [4,6-bis(cyanoamino)-1,3,5-triazin-2-yl]cyanamide Chemical compound N#CNC1=NC(NC#N)=NC(NC#N)=N1 FJJCIZWZNKZHII-UHFFFAOYSA-N 0.000 description 1
- 241001531197 [Eubacterium] hallii Species 0.000 description 1
- 241001464870 [Ruminococcus] torques Species 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000004658 acute-phase response Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- JKQXZKUSFCKOGQ-LOFNIBRQSA-N all-trans-Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C JKQXZKUSFCKOGQ-LOFNIBRQSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- CMQZRJBJDCVIEY-JEOLMMCMSA-N alpha-L-Fucp-(1->3)-[beta-D-Galp-(1->4)]-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-D-Glcp Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](CO)O[C@@H](O[C@@H]2[C@H]([C@H](O[C@@H]3[C@H](OC(O)[C@H](O)[C@H]3O)CO)O[C@H](CO)[C@@H]2O)O)[C@@H]1NC(C)=O CMQZRJBJDCVIEY-JEOLMMCMSA-N 0.000 description 1
- 235000010208 anthocyanin Nutrition 0.000 description 1
- 239000004410 anthocyanin Substances 0.000 description 1
- 229930002877 anthocyanin Natural products 0.000 description 1
- 150000004636 anthocyanins Chemical class 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- 239000000305 astragalus gummifer gum Substances 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 230000007147 bacterial dysbiosis Effects 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 238000010352 biotechnological method Methods 0.000 description 1
- 208000024330 bloating Diseases 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 235000021014 blueberries Nutrition 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 235000021152 breakfast Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 1
- 239000001354 calcium citrate Substances 0.000 description 1
- 229960004256 calcium citrate Drugs 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 229960001714 calcium phosphate Drugs 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229960004203 carnitine Drugs 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- 229940021722 caseins Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 description 1
- 229960003178 choline chloride Drugs 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- QSWDMMVNRMROPK-UHFFFAOYSA-K chromium(3+) trichloride Chemical compound [Cl-].[Cl-].[Cl-].[Cr+3] QSWDMMVNRMROPK-UHFFFAOYSA-K 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 230000008045 co-localization Effects 0.000 description 1
- 239000000701 coagulant Substances 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- 229940110767 coenzyme Q10 Drugs 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 229940124301 concurrent medication Drugs 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 229960002433 cysteine Drugs 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000007140 dysbiosis Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 230000019439 energy homeostasis Effects 0.000 description 1
- 210000001842 enterocyte Anatomy 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 208000030941 fetal growth restriction Diseases 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 229940068517 fruit extracts Drugs 0.000 description 1
- 125000002446 fucosyl group Chemical group C1([C@@H](O)[C@H](O)[C@H](O)[C@@H](O1)C)* 0.000 description 1
- 235000019525 fullness Nutrition 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 235000021255 galacto-oligosaccharides Nutrition 0.000 description 1
- 150000003271 galactooligosaccharides Chemical class 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000010492 gellan gum Nutrition 0.000 description 1
- 239000000216 gellan gum Substances 0.000 description 1
- 208000004104 gestational diabetes Diseases 0.000 description 1
- 229940046240 glucomannan Drugs 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 229960002743 glutamine Drugs 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 229920000591 gum Polymers 0.000 description 1
- 210000002064 heart cell Anatomy 0.000 description 1
- 210000003709 heart valve Anatomy 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 239000008241 heterogeneous mixture Substances 0.000 description 1
- 235000019534 high fructose corn syrup Nutrition 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229940071826 hydroxyethyl cellulose Drugs 0.000 description 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 1
- 201000008980 hyperinsulinism Diseases 0.000 description 1
- 208000006575 hypertriglyceridemia Diseases 0.000 description 1
- 229960003943 hypromellose Drugs 0.000 description 1
- 230000005965 immune activity Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000000899 immune system response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000266 injurious effect Effects 0.000 description 1
- 229940097708 inspra Drugs 0.000 description 1
- 210000005027 intestinal barrier Anatomy 0.000 description 1
- 230000007358 intestinal barrier function Effects 0.000 description 1
- 210000005206 intestinal lamina propria Anatomy 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- CMQZRJBJDCVIEY-UHFFFAOYSA-N lacto-N-fucopentaose III Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(C(O)C(O)C(CO)O2)O)C(CO)OC(OC2C(C(OC3C(OC(O)C(O)C3O)CO)OC(CO)C2O)O)C1NC(C)=O CMQZRJBJDCVIEY-UHFFFAOYSA-N 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 229930013686 lignan Natural products 0.000 description 1
- 235000009408 lignans Nutrition 0.000 description 1
- 150000005692 lignans Chemical class 0.000 description 1
- 230000004132 lipogenesis Effects 0.000 description 1
- 235000014666 liquid concentrate Nutrition 0.000 description 1
- 239000012263 liquid product Substances 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 208000018883 loss of balance Diseases 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 229960002337 magnesium chloride Drugs 0.000 description 1
- 235000011147 magnesium chloride Nutrition 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- 229960000869 magnesium oxide Drugs 0.000 description 1
- 235000012245 magnesium oxide Nutrition 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 239000011702 manganese sulphate Substances 0.000 description 1
- 235000007079 manganese sulphate Nutrition 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000003818 metabolic dysfunction Effects 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229960004452 methionine Drugs 0.000 description 1
- 229960002900 methylcellulose Drugs 0.000 description 1
- 238000012543 microbiological analysis Methods 0.000 description 1
- 244000005706 microflora Species 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- 150000002772 monosaccharides Chemical group 0.000 description 1
- 239000012120 mounting media Substances 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 230000004682 mucosal barrier function Effects 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 235000006180 nutrition needs Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 235000020823 overnutrition Nutrition 0.000 description 1
- 239000003346 palm kernel oil Substances 0.000 description 1
- 235000019865 palm kernel oil Nutrition 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 235000019175 phylloquinone Nutrition 0.000 description 1
- 239000011772 phylloquinone Substances 0.000 description 1
- MBWXNTAXLNYFJB-NKFFZRIASA-N phylloquinone Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CCC[C@H](C)CCC[C@H](C)CCCC(C)C)=C(C)C(=O)C2=C1 MBWXNTAXLNYFJB-NKFFZRIASA-N 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229960001898 phytomenadione Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000002378 plant sterols Nutrition 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229950005134 polycarbophil Drugs 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 229960002816 potassium chloride Drugs 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- 229960004839 potassium iodide Drugs 0.000 description 1
- 235000007715 potassium iodide Nutrition 0.000 description 1
- 239000003286 potassium sparing diuretic agent Substances 0.000 description 1
- 229940097241 potassium-sparing diuretic Drugs 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 235000020991 processed meat Nutrition 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 235000019423 pullulan Nutrition 0.000 description 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 1
- 229960004172 pyridoxine hydrochloride Drugs 0.000 description 1
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000003087 receptor blocking agent Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 235000020989 red meat Nutrition 0.000 description 1
- 231100000272 reduced body weight Toxicity 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000003893 regulation of appetite Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000000246 remedial effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 239000011769 retinyl palmitate Substances 0.000 description 1
- 229940108325 retinyl palmitate Drugs 0.000 description 1
- 235000019172 retinyl palmitate Nutrition 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000021003 saturated fats Nutrition 0.000 description 1
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 208000011818 severe chest pain Diseases 0.000 description 1
- 125000005630 sialyl group Chemical group 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 1
- 235000010378 sodium ascorbate Nutrition 0.000 description 1
- 229960005055 sodium ascorbate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229960001790 sodium citrate Drugs 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- 239000011684 sodium molybdate Substances 0.000 description 1
- 235000015393 sodium molybdate Nutrition 0.000 description 1
- TVXXNOYZHKPKGW-UHFFFAOYSA-N sodium molybdate (anhydrous) Chemical compound [Na+].[Na+].[O-][Mo]([O-])(=O)=O TVXXNOYZHKPKGW-UHFFFAOYSA-N 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 229960003339 sodium phosphate Drugs 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 239000011655 sodium selenate Substances 0.000 description 1
- 235000018716 sodium selenate Nutrition 0.000 description 1
- 229960001881 sodium selenate Drugs 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 229940071440 soy protein isolate Drugs 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 229960002256 spironolactone Drugs 0.000 description 1
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000011885 synergistic combination Substances 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 235000019191 thiamine mononitrate Nutrition 0.000 description 1
- 239000011748 thiamine mononitrate Substances 0.000 description 1
- UIERGBJEBXXIGO-UHFFFAOYSA-N thiamine mononitrate Chemical compound [O-][N+]([O-])=O.CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N UIERGBJEBXXIGO-UHFFFAOYSA-N 0.000 description 1
- 229960004860 thiamine mononitrate Drugs 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 229910052718 tin Inorganic materials 0.000 description 1
- 239000011135 tin Substances 0.000 description 1
- 230000003867 tiredness Effects 0.000 description 1
- 208000016255 tiredness Diseases 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 125000002640 tocopherol group Chemical class 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 235000021139 traditional diet Nutrition 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 235000013337 tricalcium citrate Nutrition 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- PHYFQTYBJUILEZ-IUPFWZBJSA-N triolein Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CCCCCCCC)COC(=O)CCCCCCC\C=C/CCCCCCCC PHYFQTYBJUILEZ-IUPFWZBJSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 229960004799 tryptophan Drugs 0.000 description 1
- 229960004441 tyrosine Drugs 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 229910052720 vanadium Inorganic materials 0.000 description 1
- GPPXJZIENCGNKB-UHFFFAOYSA-N vanadium Chemical compound [V]#[V] GPPXJZIENCGNKB-UHFFFAOYSA-N 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- 235000005282 vitamin D3 Nutrition 0.000 description 1
- 239000011647 vitamin D3 Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940021056 vitamin d3 Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000010294 whole body metabolism Effects 0.000 description 1
- 235000010930 zeaxanthin Nutrition 0.000 description 1
- 239000001775 zeaxanthin Substances 0.000 description 1
- 229940043269 zeaxanthin Drugs 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- 239000011686 zinc sulphate Substances 0.000 description 1
- 235000009529 zinc sulphate Nutrition 0.000 description 1
- 108010027843 zonulin Proteins 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- This invention relates to a method and composition for regulating satiety and stabilising or reducing insulin resistance and risk of, preventing, or treating CVD and associated comorbidities in humans, in particular in overweight or obese human individuals.
- Overweight and obesity is commonly associated with accumulated abdominal visceral fat and can be related to psycho-sociological behavioural disorders. It is often associated with the development of several chronic complications, such as high fasting glucose levels
- hypoglycaemia hyperglycaemia
- elevated triglyceride levels hypertriglyceridemia
- low levels of high density lipoprotein dyslipidaemia
- high blood pressure hypertension
- Individuals who meet at least three of these criteria are clinically diagnosed as having metabolic syndrome, which increases the risk of developing metabolic diseases such as type 2 diabetes and cardiovascular diseases (CVD) (Boulange et al., Genome Medicine 8 , 42 (2016)) .
- CVD cardiovascular diseases
- Tissue resistance to insulin's actions has been postulated as the initial impairment underlying the onset of the metabolic comorbidities in these patients.
- Type 2 diabetes is a metabolic disorder that is characterised by hyperglycaemia due to insulin resistance and relative lack of insulin and is a rapidly growing global epidemic.
- IDF Diabetes Atlas International Diabetes Federation
- WHO furthermore estimates that 90 percent of people around the world who suffer from diabetes suffer from type 2 diabetes. Long-term complications from high blood sugar can include heart disease, strokes, diabetic retinopathy, kidney failure, and poor blood flow in the limbs.
- High low-density lipoprotein cholesterol (LDL-C) and triglyceride concentrations and low high- density lipoprotein cholesterol (HDL-C) in the blood is a precursor to hypertension, hyperlipidaemia, and causes the formation and build-up of atherosclerotic plaque in the arteries leading to higher risk of CVD.
- Cardiovascular risk factors are not only observed in adults, but also obese children and young adults suffer from dyslipidaemia, hypertension, hyperinsulinemia or insulin resistance (Bridger, Paediatr. Child Health 1 4 , 177 (2009)) .
- Cholesterol concentrations within the circulatory pool are products of input from gut absorption and endogenous synthesis relative to clearance through hepatic and extrahepatic tissue pathways. A disruption in any of these mechanisms can alter this balance, which is reflected in plasma cholesterol concentrations and subsequent CVD progression (Matthan et al. J. Am. Heart Assoc. 2 , e005066 (2013)) .
- Gut microbiota is a specific entity within the body which has its own genome and whose gene pool is much more abundant than the one of its host. It has been estimated that the human intestine harbours 10 13 to 10 14 bacterial cells and the number of bacteria outnumbers the total number of cells in the body by a factor of 10 (Gill et al. , Science 31 2 , 1355 (2006)) . The physiologic functions attributed to gut microbiota have extended to extra-intestinal tissues, such as the liver, brain and adipose tissue, constructing connections with obesity and related disorders including type 2 diabetes and CVD.
- gut microbiota has the potential to affect gut permeability and, consequently, give rise to metabolic endotoxemia and higher plasma lipopolysaccharide (LPS) .
- gut peptides such as glucagon-like peptide 2 (GLP2) can play a key role in these processes (Tremaroli et al. Nature 489 , 242 (2012)) .
- GLP2 which is secreted by intestine L cells, is a key regulator of intestinal permeability (Cani et al. Gut 58 , 1091 (2009)) .
- Therapeutic regimes that target intestinal microbiota and intestinal barrier therefore show a broad prospect in treating metabolic diseases such as diabetes (Kootte et al. Diabetes, Obesity & Metabolism 1 4 , 112 (2012)) .
- the gut microbiota does not only participate in whole-body metabolism by affecting energy balance (Turnbaugh et al. Nature 444 , 1027 (2006)) and glucose metabolism (Cani et al. Diabetes 57 , 1470 (2008)) but is also involved in development of the low-grade inflammation (Cani et al. Gut 58 , 1091 (2009)) associated with obesity and related metabolic disorders such as diabetes.
- the association between inflammation and type 2 diabetes was described in the 1950s, when epidemiological studies showed a rise in acute-phase response proteins in serum of type 2 diabetic patients compared with controls (Fearnley et al. Lancet 274 , 1067 ( 1961)) .
- GLP1 and PYY are of relevance to appetite and weight maintenance because they have action on the gastrointestinal tract as well as the direct regulation of appetite.
- regulation of these hormones in humans can reduce food intake, appetite and hunger, and promote fullness and satiety with the ultimate result of promoting weight loss (Shah, Rev. Endocr. Metab. Disord. 1 5 , 181 (2014)) .
- beneficial bacteria such as bifidobacteria have shown to ameliorate both metabolic and immunological dysfunctions related to obesity.
- Bifidobacterium pseudocatenulatum has shown to reduce serum cholesterol, triglyceride and glucose levels and decrease insulin resistance and improve glucose tolerance in obese mice.
- the species can reduce liver steatosis and the number of larger adipocytes in enterocytes of obese mice (Cano et al., Obesity, 21 , 2310 (2013)) .
- bile salt hydrolase BSH
- Some bifidobacteria have high BSH activity promoting deconjugation of bile acids in the gut to secondary amino acid conj ugates. When these secondary conj ugates are excreted, cholesterol is broken down to replace the processed bile salts. Overall, this process promotes the catabolism of cholesterol, leading to reduced serum levels (Ettinger et al., Gut Microbes 5 , 719 (2014)) .
- SCFA short chain fatty acids
- Acetate has shown to be negatively associated with visceral adipose tissue and insulin levels in obese individuals and propionate has shown to reduce lipogenesis and cholesterol synthesis inhibition (Verbeke et al. , Nutrition Research Reviews 28 , 42 (2015)) .
- Selective stimulation of specific beneficial intestinal bacteria to promote their growth and metabolic activity could be a helpful approach in creating an intestinal environment that is able to regulate metabolic functions and energy balance.
- a study has described that consuming inulin increased the gut microbiota fermentation, decreased appetite, improved postprandial glucose responses and higher concentrations of GLP1 and PYY after two weeks of prebiotic treatment (Cani et al. , Am. J. Clin. Nutr. 90 , 1236 (2009)) .
- inulin may provoke side effects such as bloating, abdominal pain and increased flatulence.
- Probiotic supplementation could be an approach, however, the addition of a small number of different probiotics to the intestine is unlikely to fully promote a beneficial intestinal microbiota composition with sufficient production of metabolites.
- HMOs Human milk oligosaccharides
- Human milk oligosaccharides are a heterogeneous mixture of soluble glycans found in human milk. They are the third most abundant solid component after lactose and lipids in human milk and are present in concentrations of 5-25 g/l (Gabrielli et al., Pediatrics 1 28 , 1520 (2011)) . HMOs are resistant to enzymatic hydrolysis in the small intestine and are thus largely undigested and unabsorbed (ten Bruggencate et al. , Nutrition Reviews 72 , 377 (2014)) . The majority of HMO that reaches the colon serves as a substrate to shape the gut ecosystem by selectively stimulating the growth of specific beneficial bacteria .
- HMOs are believed to substantially modulate the infant gut microbiota and play a decisive role in the differences in the microbiota of formula-fed and breast-fed infants. These differences include the predominance of Bifidobacterium in the gut of breast-fed infants compared to a more diverse gut microbiota in formula-fed infants (Bezirtzoglou et al., Anaerobe 1 7 , 478 (2011) . This is viewed as beneficial for the infant because strains of Bifidobacterium species and their metabolites are believed to have a positive effect on human health (Chichlowski et al., J. Pediatr. Gastroenterol. Nutr. 55 , 321 (2012) ; Fukuda et al. , Nature 469 , 543 (2011)) .
- sialylated and fucosylated HMOs has a positive effect on the growth of certain strains of bifidobacteria that are typically found in both infant and adult microbiota (WO 2013/154725) .
- EP-A- 1332759 discloses that oral doses of 2'-FL, 3'-SL, 6'-SL, LNnT and sialic acid promote insulin secretion in type 2 diabetes-model mice.
- EP-A-2143341 discloses that a mixture of GOS, sialylated oligosaccharides and N-acylated oligosaccharides reduces triglyceride concentration in liver in model mice.
- EP-A-2332552 discloses that 3'-SL and 6'-SL reduce/prevent fat accumulation in the liver and other organs in high-fat diet mice and rats.
- WO 2013/057061 discloses a composition for increasing insulin sensitivity and/or reducing insulin resistance that contains long chain polyunsaturated fatty acids, probiotics and a mixture of oligosaccharides containing at least one of lacto-N-neotetraose (LNnT) and lacto- N-tetraose (LNT), at least one N-acetylated oligosaccharide different from LNnT and LNT, at least one sialylated oligosaccharide and at least one neutral oligosaccharide.
- This composition can also contain 2'-0-fucosyllactose (2'-FL) .
- the composition is particularly adapted for use in infants who were born preterm and/or who experienced IUGR, and in pregnant women suffering from gestational diabetes. It is also stated that the composition can be given to children, adolescents and adults suffering from insulin resistance and/or type II diabetes. It is stated that the efficacy of the composition can be the result of the synergistic combination of immunity modulator effects triggered by the probiotics and the LC-PUFA through their stimulation with the specific oligosaccharide mixture.
- WO 2013/036104 discloses a method for inter alia improving regulation of satiety in a human subject having an age of 0 to 36 months by feeding a nutritional composition comprising lipid globules.
- WO 2014/ 187464 discloses a synthetic mixture of oligosaccharides comprising at least 6 oligosaccharides selected from fucosylated, sialylated, sulfated, GlcNAc- GalNAc- and mannose-containing oligosaccharides, for treating a microbiota of a human, to reduce or eliminate the activity and/or the proportion of a microbe in the microbiota that is associated with the development or maintenance of a cardiovascular disease.
- a metabolic disorder for example obesity, obesity induced pre-diabetes and obesity induced type 2 diabetes
- an obesity-related metabolic disorder for example obesity, obesity induced pre-diabetes and obesity induced type 2 diabetes; and/or
- CVD or CVD-associated pathologic condition or disease in a human, preferably, in an overweight or obese human individual.
- a first aspect of this invention relates to one or more human milk
- an obesity-related metabolic disorder for example obesity, obesity induced pre-diabetes and obesity induced type 2 diabetes
- CVD cardiovascular disease
- CVD-associated pathological condition or disease in a human preferably, in an overweight or obese human individual
- CVD cardiovascular disease
- CVD-associated pathological condition or disease in a human preferably, in an overweight or obese human individual
- CVD cardiovascular disease
- CVD-associated pathological condition or disease in a human preferably, in an overweight or obese human individual
- CVD cardiovascular disease
- CVD-associated pathological condition or disease in a human, preferably, in an overweight or obese human individual.
- the one or more HMOs is/are lacto-N-tetraose (LNT), lacto-N- neotetraose (LNnT), 2'-fucosyllactose (2'-FL), lacto-N-fucopentaose I (LNFP-I), 3- fucosyllactose (3-FL), difucosyllactose (DFL), 3'-sialyllactose (3'-SL) or 6'-sialyllactose (6'- SL), or a mixture thereof.
- LNT lacto-N-tetraose
- LNnT lacto-N- neotetraose
- 2'-FL lacto-N-fucopentaose I
- 3- fucosyllactose 3- fucosyllactose
- DFL difucosyllactose
- 3'-SL 3'-sialyllact
- a second aspect of the invention relates to one or more human milk oligosaccharides (HMOs) selected from the group consisting of fucosylated HMOs and non-fucosylated HMOs, preferably a mixture of one or more fucosylated HMOs and one or more non-fucosylated neutral HMOs, for use in increasing the abundance of bifidobacteria in a human, preferably in an overweight or obese human having a propensity of, or diagnosed with a cardiovascular disease (CVD).
- HMOs human milk oligosaccharides
- a third aspect of the invention relates to a synthetic composition for use in
- composition comprising an effective amount of one or more human milk oligosaccharides
- an obesity-related metabolic disorder for example obesity, obesity induced pre-diabetes and obesity induced type 2 diabetes
- CVD cardiovascular disease
- CVD-associated pathological condition or disease in a human, preferably, in an overweight or obese human individual
- CVD cardiovascular disease
- CVD-associated pathological condition or disease in a human, preferably, in an overweight or obese human individual, and/or
- CVD cardiovascular disease
- CVD-associated pathological condition or disease in a human, preferably in an overweight or obese human individual
- the synthetic composition comprising an effective amount of one or more human milk oligosaccharides (HMOs), for example those specified in the first aspect.
- HMOs human milk oligosaccharides
- the amount of a human milk oligosaccharide is effective to increase the abundance, particularly the relative abundance, of bifidobacteria in the gastrointestinal tract of the human.
- the bifidobacteria increased is a member of the phylogenetic Bifidobacterium adolescentis group, for example, Bifidobacterium pseudocatenulatum and/or Bifidobacterium adolescentis, and, after about 14 days of treatment, are Bifidobacterium longum and/or Bifidobacterium bifidum .
- a fourth aspect of the invention relates to a synthetic composition for use in increasing the abundance of bifidobacteria in a human, preferably, in an overweight or obese human having a propensity of, or diagnosed with a cardiovascular disease (CVD), the synthetic composition comprising one or more human milk oligosaccharides (HMOs) selected from the group consisting of fucosylated HMOs and non-fucosylated neutral HMOs, preferably a mixture of one or more fucosylated HMOs and one or more non-fucosylated neutral HMOs.
- HMOs human milk oligosaccharides
- a fifth aspect of this invention provides a method for
- an obesity-related metabolic disorder for example obesity, obesity induced pre-diabetes and obesity induced type 2 diabetes
- CVD cardiovascular disease
- CVD-associated pathological condition or disease in a human, preferably, in an overweight or obese human individual
- CVD cardiovascular disease
- CVD-associated pathological condition or disease in a human, preferably, in an overweight or obese human individual, and/or
- CVD cardiovascular disease
- CVD-associated pathological condition or disease in a human, preferably, in an overweight or obese human individual
- the method comprising administering, to the human, an effective amount of one or more human milk oligosaccharides, or a synthetic composition comprising an effective amount of one or more human milk oligosaccharides.
- a sixth aspect of the invention relates to a method for increasing the a bundance of bifidobacteria in a human, preferably in an overweight or obese human having a propensity of, or diagnosed with a cardiovascular disease (CVD), the method comprising administering, to the human, one or more human milk oligosaccharides (HMOs) selected from the group consisting of fucosylated HMOs and core HMOs, preferably of a mixture of one or more fucosylated HMOs and one or more core HMOs, or a synthetic composition comprising one or more human milk oligosaccharides (HMOs) selected from the group consisting of fucosylated HMOs and core HMOs, preferably of a mixture of one or more fucosylated HMOs and one or more core HMOs.
- HMOs human milk oligosaccharides
- the one or more HMOs are administered to a human in need in two steps:
- patient means a human individual who was diagnosed by a medical or health professional personal as having a disease, e.g . a metabolic disorder, and receiving or registered to receive medical treatment.
- the patient can be a paediatric or adult patient.
- An embodiment of the patent e.g. is an overweight or obese individual that is having a CVD or a CVD-associated pathological condition or disease.
- Paediatric patient can be a human patient of 3-21 years old .
- a “patient” can also be any other mammal.
- non-infant human and “non-infant” all mean in the present context a human individual of at least 3 years old .
- a human can be a child, a teenager, an adult or an elderly adult, preferably, the human is an individual of at least 3 years old that has an excess of body fat, more preferably, an individual whose excess body fat has accumulated to the extent that it may have a negative effect on health, i.e. an overweight or obese human individual.
- Body fat percentage preferably means total mass of body fat divided by total mass of the body.
- obese human or "obese human individual” means that a human individual that has a body mass index (BMI), a measurement obtained by dividing the individual's weight by the square of the individual's height, over 30 kg/m 2 , with the range 25-30 kg/m 2 defined as overweight.
- BMI body mass index
- Overweight and obesity for children and teens is defined as the following : overweight is defined as a BMI at or above the 85th percentile and below the 95th percentile for children and teens of the same age and sex. Obesity is defined as a BMI at or above the 95th percentile for children and teens of the same age and sex (see: Rolland-Cachera, Int. J. Pediatr. Obesity 6 , 325 (2011)) .
- metabolic disorder also known as “metabolic syndrome” in the present context means an inherited or acquired genetic or physiological condition which is reflected by a change in metabolism of an individual, typically is a clustering of at least three of the five following medical conditions (giving a total of 16 possible combinations giving the syndrome) : abdominal (central) obesity (cf. TOFI)
- HDL high-density lipoprotein
- Metabolic syndrome is associated with the risk of
- the invention relates to metabolic disorders, such as obesity, obesity induced pre-diabetes, obesity induced type 2 diabetes.
- a metabolic disorder is insulin resistance or is associated with insulin resistance.
- insulin resistance means a pathological condition in an individual who has a reduced insulin activity, e.g. due to the individual's cells fail to respond normally to the hormone insulin, or insulin is underproduced in the individual's body, or it has altered activity.
- insulin resistance is in an overweight or obese individual.
- Cardiovascular disease refers broadly to any disease of the heart and circulatory system (arteries and veins) . Cardiovascular disease generally refers to conditions that involve narrowed or blocked blood vessels that can lead to a heart attack, chest pain
- angina or stroke.
- Other heart conditions such as those that affect the heart muscle, valves or rhythm, also are also contemplated as forms of heart disease.
- CVD include, but not limited to, coronary artery disease (blockage of blood vessels that serve the heart), acute coronary syndrome (symptoms such as pain, weakness, and tiredness caused by coronary artery disease), angina pectoris (pain resulting from coronary artery disease or other causes), myocardial infarction (heart attack, with damage to heart muscle caused by coronary artery disease), and left ventricular thrombus (blood clot in the left side of the heart that pumps blood into your body) .
- coronary artery disease blockage of blood vessels that serve the heart
- acute coronary syndrome symptoms such as pain, weakness, and tiredness caused by coronary artery disease
- angina pectoris pain resulting from coronary artery disease or other causes
- myocardial infarction heart attack, with damage to heart muscle caused by coronary artery disease
- CVD may be accompanied with health complications (that are interchangeably referred herein as pathologic conditions) or associated diseases, which are also contemplated herein.
- health complications that are interchangeably referred herein as pathologic conditions
- CVD-associated diseases/pathologic conditions include heart failure (occurs when the heart cannot adequately pump blood throughout the body; this can cause shortness of breath, dizziness, confusion, and the build-up of fluid in the body, causing swelling), heart attack (occurs when the coronary arteries narrow so much that they cut off blood supply to the heart; the heart cells begin to die as they are deprived of oxygen and symptoms include shortness of breath and severe chest pain that may radiate to the back, jaw, or left arm), stroke (occurs due formation and lodging of blood clots in a blood vessel in the brain and cutting thus off blood flow; stroke symptoms include : numbness on one side of the body, confusion, trouble, speaking, loss of balance or coordination), pulmonary embolism (is similar to a stroke, but the blocked blood vessel is in the lungs instead of the
- propensity in the present context means natural tendency of a human individual to develop later in life a medical condition, such as a disease, in particular a CVD or a CVD- associated pathological condition or disease.
- preventing CVD and/or CVD associated pathological condition or disease in the present context means eliminating or minimising a chance of development of a CVD disease or a pathological condition or disease associated with an CVD. Both primary and secondary prevention are thus contemplated.
- the primary prevention means preventing a CVD or associated disease or condition before it occurs, and the secondary prevention means preventing additional attacks of a CVD or development of associated condition or disease after the first attack has occurred .
- enteral administration preferably means any conventional form for delivery of a composition to a human that causes the deposition of the composition in the gastrointestinal tract (including the stomach) .
- Methods of enteral administration include feeding through a naso-gastric tube or jej unum tube, oral, sublingual and rectal.
- oral administration preferably means delivery into the gastrointestinal tract through the oral cavity.
- oral administration is a form of enteral administration.
- the term "effective amount” preferably means an amount of a human milk oligosaccharide or an amount of a composition that provides a human milk oligosaccharide sufficient to render a desired treatment outcome in a patient.
- An effective amount can be administered in one or more doses to the patient to achieve the desired treatment outcome.
- the term "effective amount” may mean an amount of a single HMO, or a combination of different HMOs that is capable of increasing the abundance of bifidobacteria in the gastro- intestinal tract of a human individual of the invention, preferably, relative abundance of members of the Bifidobacterium adolescentis phylogenetic group in particular B. adolescentis and/or B. pseudocatenulatum .
- the term "relative abundance of bifidobacteria” means the abundance of bifidobacteria relative to other genus in the microbiota of the gastro-intestinal tract.
- human milk oligosaccharide or "HMO” preferably means a complex carbohydrate consisting of a small number, typically 3- 10, of monosaccharide units attached to each other by an interglycosidic linkage that can be found in human breast milk and that can be in acidic or neutral form. More than about 200 different HMO structures are known to exist in human breast milk (Urashima et al. : Milk Oligosaccharides, Nova Biomedical Books, New York, 2011) . HMOs can be core, fucosylated and sialylated oligosaccharides.
- Core HMOs are non- fucosylated neutral (that is non-charged) HMOs and consist of Glu, Gal and GlcNAc (thus devoid of Fuc and sialic acid) .
- core HMOs include lacto-N-tetraose (LNT), lacto- N-neotetraose (LNnT), lacto-N-neohexaose (LNnH) , lacto-N-hexaose (LNH) and p-lacto-N- neohexaose (pLNnH) .
- Fucosyl HMOs are fucosylated lactoses or fucosylated core HMOs such as 2'-fucosyllactose (2'-FL), lacto-N-fucopentaose I (LNFP-I), lacto-N-difucohexaose I (LNDFH-I), 3-fucosyllactose (3-FL), difucosyllactose (DFL), lacto-N-fucopentaose III (LNFP- III), fucosyl-para-lacto-N-neohexaose (F-pLNnH), lacto-N-difucohexaose I (LNDFH-I), fucosyl-lacto-N-hexaose II (FLNH-II), lacto-N-fucopentaose V (LNFP-V), lacto-N- difucohexaose II (LNDFH-
- Sialyl HMOs are sialylated lactoses or sialylated core HMOs such as 3',6-disialyllacto-N-tetraose (DSLNT), 6'-sialyllactose (6'-SL), 3'-sialyllactose (3'-SL), 6'-sialyllacto-N-neotetraose (LST c), 3'-sialyllacto-N-tetraose (LST a) and 6-sialyllacto-N-tetraose (LST b) .
- DSLNT 3',6-disialyllacto-N-tetraose
- 6'-SL 6'-sialyllactose
- 3'-SL 6'-sialyllactose
- LST c 6'-sialyllacto-N-neot
- sialylated and fucosylated HMOs include disialyl-fucosyl-lacto-N-hexaose II (DSFLNH-II), fucosyl-sialyl-lacto-N-neohexaose I (FSLNnH-I), fucosyl-sialyl-lacto-N-hexaose I (FSLNH-I) and 3-fucosyl-3'-sialyllactose (FSL) .
- DSFLNH-II disialyl-fucosyl-lacto-N-hexaose II
- FSLNnH-I fucosyl-sialyl-lacto-N-neohexaose I
- FSLNH-I fucosyl-sialyl-lacto-N-hexaose I
- FSL 3-fucosyl-3'-sialyllactose
- Microbiota preferably mean a community of living microorganisms that typically inhabits a bodily organ or part, particularly the gastro-intestinal organs of non-infant humans.
- the most dominant members of the gastrointestinal microbiota include microorganisms of the phyla of Firmicutes, Bacteroidetes, Actinobacteria,
- Proteobacteria Synergistetes, Verrucomicrobia, Fusobacteria, and Euryarchaeota; at genus level Bacteroides, Faecalibacterium, Bifidobacterium, Roseburia, Alistipes, Collinsella, Blautia, Coprococcus, Ruminococcus, Eubacterium and Dorea; at species level Bacteroides uniformis, Alistipes putredinis, Parabacteroides merdae, Ruminococcus bromii, Dorea longicatena, Bacteroides caccae, Bacteroides thetaiotaomicron, Eubacterium hallii, Ruminococcus torques, Faecalibacterium prausnitzii, Ruminococcus lactaris, Collinsella aerofaciens, Dorea
- the gastrointestinal microbiota includes the mucosa-associated microbiota, which is located in or attached to the mucus layer covering the epithelium of the gastrointestinal tract, and luminal-associated microbiota, which is found in the lumen of the gastrointestinal tract.
- bifidobacteria means a member of the Bifidobacterium genus commonly found in the human gastro-intestinal tract.
- examples of bifidobacteria are Bifidobacterium longum, Bifidobacterium bifidum, and the members of the phylogenetic Bifidobacterium adolescentis group.
- bifidobacteria preferably include members of the phylogenetic Bifidobacterium adolescentis group, for example Bifidobacterium pseudocatenulatum and/or Bifidobacterium adolescentis.
- Bifidobacterium of the Bifidobacterium adolescentis phylogenetic group means a bacterium selected from a group consisting of Bifidobacterium adolescentis, Bifidobacterium angulatum , Bifidobacterium catenulatum, Bifidobacterium pseudocatenulatum ,
- Bifidobacterium kashiwanohense, Bifidobacterium dentum and Bifidobacterium stercoris (Duranti et al. Appl. Environ. Microbiol. 79 , 336 (2013), Bottacini et al. Microbial Cell Fact. 1 3 : S4 (2014)) .
- synthetic composition designates a composition which is artificially prepared and preferably means a composition containing at least one compound that is produced ex vivo chemically and/or biologically, e.g. by means of chemical reaction, enzymatic reaction or recombinantly.
- a synthetic composition of the invention may be, but preferably is not, identical with a naturally occurring composition.
- the synthetic composition of the invention typically comprises one or more compounds, advantageously HMOs, that are capable of preferentially increasing the abundance of bifidobacteria, in particular
- Bifidobacterium of the following species Bifidobacterium longum, Bifidobacterium bifidum, and/or members of the phylogenetic Bifidobacterium adolescentis group.
- the synthetic composition may comprise one or more compounds or components other than HMOs that may have an effect on bifidobacteria of a human subject microbiota in vivo, e.g . non-digestible oligosaccharides or prebiotics. Also in some
- the synthetic compositions may comprise one or more nutritionally or pharmaceutically active components which do not affect adversely the efficacy of the above mentioned compounds.
- a synthetic composition of the invention Some non-limiting embodiments of a synthetic composition of the invention are also described below.
- the synthetic composition can take any suitable form.
- the composition can be in the form of a nutritional composition which contains other macronutrients such as proteins, lipids or other carbohydrates.
- the synthetic composition can also be a pharmaceutical composition.
- intestinal permeability preferably means the permeability of the intestinal mucosa of a patient, permitting the absorption of vital nutrients from the gut lumen while presenting a barrier against the passage of pathogenic substances into the patient's body.
- endotoxemia preferably means the presence of endotoxins, such as gut microbiota-derived lipopolysaccharides (LPS) in the blood of a patient.
- endotoxins such as gut microbiota-derived lipopolysaccharides (LPS)
- low-grade inflammation preferably means an immune system response of a patient characterized by altered levels of pro-inflammatory and anti-inflammatory cytokines as well as numerous other markers of immune system activity in response to an inj urious stimuli.
- GI tissue index
- AUC blood glucose response curve
- the AUC of the test food is divided by the AUC of the standard (glucose, the standard, has a GI of 100) and multiplied by 100.
- the average GI value is calculated from data collected in 10 human subjects.
- initial period of treatment with an HMO or an HMO mixture is about 14 days from the start of the treatment; "additional period” of treatment means 1 or more days following the initial period of treatment.
- the HMOs can be isolated or enriched by well-known processes from milk(s) secreted by mammals including, but not limited to human, bovine, ovine, porcine, or caprine species.
- the HMOs can also be produced by well-known processes using microbial fermentation, enzymatic processes, chemical synthesis, or combinations of these technologies.
- LNnT can be made as described in WO 2011/100980 and WO 2013/044928
- LNT can be synthesized as described in WO 2012/155916 and WO 2013/044928
- a mixture of LNT and LNnT ca n be made as described in WO 2013/091660
- 2'-FL can be made as described in WO 2010/ 115934 and WO 2010/115935
- 3-FL can be made as described in WO
- sialylated oligosaccharides can be made as described in WO 2012/113404 and mixtures of human milk oligosaccharides can be made as described in WO 2012/113405.
- sialylated oligosaccharides can be made as described in WO
- fucosylated oligosaccharides can be made as described in WO 2012/127410, and advantageously diversified blends of human milk oligosaccharides can be made as described in WO 2012/156897 and WO 2012/156898.
- WO 01/04341 and WO 2007/ 101862 describe how to make core human milk oligosaccharides optionally substituted by fucose or sialic acid using genetically modified £ coli.
- Embodiments of the invention regulating satiety and/or reducing propensity to obesity
- HMOs human milk oligosaccharides
- HMOs can, by enteral ingestion, increase the production of GLP1, possibly through modulation of the intestinal microbiota in a human, in particular a non-infant human.
- GLP1 possibly through modulation of the intestinal microbiota in a human, in particular a non-infant human.
- a more beneficial intestinal microbial community can be shaped and maintained, and the regulation of satiety can be improved, leading to lower food intake. This can result in reduced propensity to obesity.
- this invention in one aspect, relates to one or more human milk
- oligosaccharides for use in a synthetic composition comprising an effective amount of one or more human milk oligosaccharides for use in, or a method for
- a mixture of 2'-FL and LNnT may contain the amount of 2'- FU LNnT form about 1.5 : 1 to about 4: 1 by weight.
- the HMO may be a single HMO or a mixture of any HMOs suitable for the purpose of the invention.
- the HMO is a fucosylated or a non-fucosylated neutral HMO.
- the invention relates to a mixture of HMOs, the mixture comprising at least a first HMO and at least a second HMO, wherein the first HMO is a fucosylated neutral HMO and the second HMO is a non-fucosylated neutral HMO.
- the mixture of HMOs may contain a fucosylated HMO selected from the list consisting of 2'-FL, 3-FL, DFL, LNFP-I, LNFP-II, LNFP- III, LNFP-V, LNDFH-I, LNDFH-II, LNDFH-III, FLNH-I, FLNH-II, FLNnH, FpLNH-I and F-pLNnH II, and a non-fucosylated HMO selected from the list consisting of LNT, LNnT, LNH, LNnH, pLNH and pLNnH .
- a fucosylated HMO selected from the list consisting of 2'-FL, 3-FL, DFL, LNFP-I, LNFP-II, LNFP- III, LNFP-V, LNDFH-I, LNDFH-II, LNDFH-III, FLNH-I, FLNH-II, FLNnH, Fp
- the mixture of HMOs contains a fucosylated HMO selected from the list consisting of 2'-FL, 3-FL and DFL, and a non-fucosylated HMO selected from the list consisting of LNT and LNnT; advantageously the mixture comprises 2'-FL and LNnT and/or LNT.
- the mixture of HMOs essentially consists of two neutral HMOs, e.g.
- a fucosylated HMO selected from the list consisting of 2'-FL, 3-FL, DFL, LNFP-I, LNFP-II, LNFP-III, LNFP-V, LNDFH-I, LNDFH-II, LNDFH-III, FLNH-I, FLNH-II, FLNnH, FpLNH-I and F- pLNnH II, and a non-fucosylated HMO selected from the list consisting of LNT, LNnT, LNH, LNnH, pLNH and pLNnH .
- the mixture essentially consists of a fucosylated HMO selected from the list consisting of 2'-FL, 3-FL and DFL, and a non-fucosylated HMO selected from the list consisting of LNT and LNnT; in one preferred embodiment the mixture essentially consists of 2'-FL and LNnT, in another preferred embodiment the mixture essentially consists of 2'-FL and LNT.
- a mixture of 2'-FL and LNnT may contain the amount of 2'- FL: LNnT form about 1.5: 1 to about 4: 1 by weight.
- HMO may comprise a single HMO or a mixture of any HMOs suitable for the purpose of the invention as disclosed above.
- the synthetic composition can take any suitable form.
- the composition can be in the form of a nutritional composition which contains other macronutrients such as proteins, lipids or other carbohydrates (see below).
- the synthetic composition can also be a
- compositions comprise an effective amount one or more HMOs described above.
- the synthetic composition may be a pharmaceutical composition.
- the synthetic composition comprises an effective amount one or more HMOs described above.
- the pharmaceutical composition can contain a pharmaceutically acceptable carrier, e.g.
- the pharmaceutical composition can also contain other materials that do not produce an adverse, allergic or otherwise unwanted reaction when administered to humans.
- the carriers and other materials can include solvents, dispersants, coatings, absorption promoting agents, controlled release agents, and one or more inert excipients, such as starches, polyols, granulating agents, microcrystalline cellulose, diluents, lubricants, binders, and disintegrating agents.
- tablet dosages of the a nti- infective compositions can be coated by standard aqueous or non-aqueous techniques.
- compositions can be administered orally, e.g. as a tablet, capsule, or pellet containing a predetermined amount, or as a powder or granules containing a predetermined concentration or a gel, paste, solution, suspension, emulsion, syrup, bolus, electuary, or slurry, in an aqueous or non-aqueous liquid, containing a predetermined concentration.
- Orally administered compositions can include binders, lubricants, inert diluents, flavouring agents, and humectants.
- Orally administered compositions such as tablets can optionally be coated and can be formulated so as to provide sustained, delayed or controlled release of the mixture therein.
- compositions can also be administered by rectal suppository, aerosol tube, naso-gastric tube or direct infusion into the GI tract or stomach.
- the pharmaceutical compositions can also include therapeutic agents such as antiviral agents, antibiotics, probiotics, analgesics, and anti-inflammatory agents.
- the proper dosage of these compositions for a human can be determined in a conventional manner, based upon factors such as severity of the lactose intolerance, immune status, body weight and age.
- a synthetic composition comprises an effective amount of a mixture of 2'-FL and LNnT, preferably the mass ratio between 2'-FL and LNnT in the composition is in the range from 5: 1 to 1 : 1.
- the invention relates to the following methods:
- a method for reducing propensity to obesity in a human having a metabolic disorder comprising administering to the human an effective amount of one or more human milk oligosaccharides.
- the amount of human milk oligosaccharide(s) required to be administered to the person will vary depending upon factors such as the risk and condition severity, the age of the person, the form of the composition, and other medications being administered to the person.
- the required amount can be readily set by a medical practitioner and would generally be in the range from about 10 mg to about 20 g per day, in certain embodiments from about 10 mg to about 15 g per day, from about 100 mg to about 10 g per day, in certain embodiments from about 500 mg to about 10 g per day, in certain embodiments from about 1 g to about 7.5 g per day.
- an appropriate dose can be determined based on several factors, including, for example, the body weight and/or condition of the patient being treated, the severity of the condition, being treated, other ailments and/or diseases of the person, the incidence and/or severity of side effects and the manner of administration. Appropriate dose ranges can be determined by methods known to those skilled in the art.
- the dosing can be higher (for example 200 mg to 20 g per day, preferably 500 mg to 15 g per day, more preferably 1 g to 10 g per day, in certain embodiments 2.5 g to 7.5 g per day).
- the dosing can be reduced (for example, 10 mg to 10 g per day, preferably 100 mg to 7.5 g per day, more preferably 500 mg to 5 g per day, in certain embodiments 1 g to 2.5 g per day).
- one or more HMOs or a composition comprising or essentially consisting thereof is administered to a human in need enteral, e.g. orally.
- a synthetic composition of this invention can be co-administered to a patient who is also receiving a standard-of-care medication for obesity or diabetes.
- Embodiments of the invention stabilising or reducing insulin resistance
- human milk oligosaccharides advantageously 2'-FL, LNT and LNnT, not only modulate inflammation and microbiota in the GI tract, but also stabilise or reduce insulin resistance. Further, the abundance of members of the
- Bifidobacterium adolescentis phylogenetic group is increased, in particular B. adolescentis and/or B. pseudocatenulatum .
- B. adolescentis and/or B. pseudocatenulatum are increased, in particular B. adolescentis and/or B. pseudocatenulatum .
- a combination of 2'-FL and LNnT preferentially increases the abundance of B. pseudocatenulatum . This can result in lower chronic inflammation, improved insulin sensitivity and reduced insulin resistance.
- Obese and pre- diabetic patients can be stabilised and the progression to diabetes slowed, stopped or reversed .
- Diabetic patients can be stabilised or at least the progression to diabetes with complications slowed .
- this invention in another embodiments, relates to one or more human milk oligosaccharides (HMOs) for use in, or a synthetic composition comprising an effective amount of one or more human milk oligosaccharides for use in, or a method for stabilising or reducing insulin resistance in a human individual having an obesity-related metabolic disorder, for example obesity, obesity induced pre-diabetes and obesity induced type 2 diabetes.
- HMOs human milk oligosaccharides
- One embodiment of the invention relates to an HMO for use in stabilising or reducing insulin resistance in a human individual having an obesity-related metabolic disorder.
- Another embodiment of the invention relates to a synthetic composition comprising an HMO for use in stabilising or reducing insulin resistance in a human individual having an obesity-related metabolic disorder.
- Still another embodiment of the invention relates to a method for stabilising or reducing insulin resistance in a human individual having an obesity-related metabolic disorder, the method comprising enterally administering to the patient an effective amount of one or more human milk oligosaccharides.
- the HMO in any of the above embodiments concerning stabilising or reducing insulin resistance in a human may be a single HMO or a mixture of any HMOs suitable for the purpose of the invention.
- the HMO is a fucosylated or a non-fucosylated neutral HMO.
- this particular aspect of the invention relates to a mixture of HMOs, the mixture comprising at least a first HMO and at least a second HMO, wherein the first HMO is a fucosylated neutral HMO and the second HMO is a non-fucosylated neutral HMO.
- the mixture of HMOs may contain a fucosylated HMO selected from the list consisting of 2'-FL, 3-FL, DFL, LNFP-I, LNFP-II, LNFP-III, LNFP-V, LNDFH-I, LNDFH-II, LNDFH- III, FLNH-I, FLNH-II, FLNnH, FpLNH-I and F-pLNnH II, and a non-fucosylated HMO selected from the list consisting of LNT, LNnT, LNH, LNnH, pLNH and pLNnH .
- a fucosylated HMO selected from the list consisting of 2'-FL, 3-FL, DFL, LNFP-I, LNFP-II, LNFP-III, LNFP-V, LNDFH-I, LNDFH-II, LNDFH- III, FLNH-I, FLNH-II, FLNnH, Fp
- the mixture of HMOs contains a fucosylated HMO selected from the list consisting of 2'-FL, 3-FL and DFL, and a non-fucosylated HMO selected from the list consisting of LNT and LNnT; advantageously the mixture comprises 2'-FL and LNnT and/or LNT.
- the mixture of HMOs essentially consists of two neutral HMOs, e.g.
- a fucosylated HMO selected from the list consisting of 2'-FL, 3-FL, DFL, LNFP-I, LNFP-II, LNFP-III, LNFP-V, LNDFH-I, LNDFH-II, LNDFH-III, FLNH-I, FLNH-II, FLNnH, FpLNH-I and F-pLNnH II, and a non- fucosylated HMO selected from the list consisting of LNT, LNnT, LNH, LNnH, pLNH and pLNnH.
- the mixture essentially consists of a fucosylated HMO selected from the list consisting of 2'-FL, 3-FL and DFL, and a non-fucosylated HMO selected from the list consisting of LNT and LNnT; in one preferred embodiment the mixture essentially consists of 2'-FL and LNnT, in another preferred embodiment the mixture essentially consists of 2'-FL and LNT.
- the invention relates in different embodiments to single HMOs as substantially pure single compounds, i.e. an HMO which grade of purity satisfies the demand of a medical or food authority for marketing, or mixtures of substantially pure HMOs, or artificial compositions comprising one or more HMOs.
- the human milk oligosaccharides include one or more fucosylated HMOs, such as 2'-FL, and one or more core HMOs, such as LNT and LNnT. More preferably the composition comprises a mix of 2'-FL and LNnT; for example in a mass ratio of 5: 1 to 1 : 1; more preferably 4: 1 to 2: 1.
- the human individual can be an obese paediatric or adult patient, preferably a prepubescent child.
- the HMOs may be administered to the patient as a daily dose of about 1 g to about 15 g such as from about 3 g to about 10 g.
- the patient can be administered a higher amount, preferably 5 g to 10 g per day, of the HMOs for an initial treatment period, followed by a lower amount, preferably 1 g to 5 g per day, for a
- the initial treatment period can be 1 to 8 weeks.
- the maintenance period is at least 1 month.
- the synthetic composition can take any suitable form.
- the composition can be in the form of a nutritional composition which contains other macronutrients such as proteins, lipids or other carbohydrates (see below).
- the synthetic composition can also be a
- compositions comprise an effective amount one or more HMOs described above.
- the synthetic composition may be a pharmaceutical composition.
- the synthetic composition comprises an effective amount one or more HMOs described above.
- the pharmaceutical composition can contain a pharmaceutically acceptable carrier, e.g.
- the pharmaceutical composition can also contain other materials that do not produce an adverse, allergic or otherwise unwanted reaction when administered to humans.
- the carriers and other materials can include solvents, dispersants, coatings, absorption promoting agents, controlled release agents, and one or more inert excipients, such as starches, polyols, granulating agents, microcrystalline cellulose, diluents, lubricants, binders, and disintegrating agents.
- tablet dosages of the a nti- infective compositions can be coated by standard aqueous or non-aqueous techniques.
- compositions can be administered orally, e.g. as a tablet, capsule, or pellet containing a predetermined amount, or as a powder or granules containing a predetermined concentration or a gel, paste, solution, suspension, emulsion, syrup, bolus, electuary, or slurry, in an aqueous or non-aqueous liquid, containing a predetermined concentration.
- Orally administered compositions can include binders, lubricants, inert diluents, flavouring agents, and humectants.
- Orally administered compositions such as tablets can optionally be coated and can be formulated so as to provide sustained, delayed or controlled release of the mixture therein.
- compositions can also be administered by rectal suppository, aerosol tube, naso-gastric tube or direct infusion into the GI tract or stomach.
- the pharmaceutical compositions can also include therapeutic agents such as antiviral agents, antibiotics, probiotics, analgesics, and anti-inflammatory agents.
- therapeutic agents such as antiviral agents, antibiotics, probiotics, analgesics, and anti-inflammatory agents.
- the proper dosage of these compositions for a human can be determined in a conventional manner, based upon factors such as severity of the lactose intolerance, immune status, body weight and age.
- the amount of human milk oligosaccharide(s) required to be administered to the person will vary depending upon factors such as the risk and condition severity, the age of the person, the form of the composition, and other medications being administered to the person.
- the required amount can be readily set by a medical practitioner and would generally be in the range from about 200 mg to about 20 g per day, in certain embodiments from about 1 g to about 15 g per day, from about 3 g to about 10 g per day, in certain embodiments from about 3 g to about 7.5 g per day.
- An appropriate dose can be determined based on several factors, including, for example, body weight and/or condition, the severity of the condition, being treated or prevented, other ailments and/or diseases, the incidence and/or severity of side effects and the manner of administration. Appropriate dose ranges may be determined by methods known to those skilled in the art.
- the dosing can be higher or lower depending upon the need to boost bifidobacteria abundance or initial tolerance to HMOs.
- the dosing can be set for chronic long term use.
- the dosing can be 500 mg to 20 g per day, preferably 1 g to 15 g per day, more preferably 3 g to 10 g per day.
- the dosing can be reduced to 200 mg to 10 g per day, preferably 500 mg to 7.5 g per day, more preferably 1 g to 5 g per day.
- a synthetic composition of this invention can be co-administered to a patient who is also receiving a standard-of-care medication for obesity or diabetes.
- HMO/HMOs or synthetic composition(s) comprising said HMO/HMOs disclosed herein is(are) preferably administered to a patient in need enterally, e.g . orally.
- Embodiments of the invention reducing the risk of, preventing or treating CVD and associated co-morbidities in overweight or obese humans
- HMOs oligosaccharides
- HMOs can, by oral or enteral ingestion, increase the production of SCFA and activity of BSH, possibly through modulation of the intestinal microbiota in human.
- a more beneficial intestinal microbial community can be shaped and maintained, which contributes to attenuation of hypercholesterolemia and hypertension . This can result in reduced risk of, prevention of and/or treatment of, CVD and associated co-morbidities.
- this invention in other embodiments, relates to a human milk oligosaccharide or a mixture of two to five human milk oligosaccharides for use in, or a synthetic composition comprising an effective amount of a human milk oligosaccharide or an effective amount of a mixture of two to five human milk oligosaccharides for use in, or a method for
- CVD cardiovascular disease
- CVD-associated pathological condition or disease in a human, preferably, in an overweight or obese human individual
- CVD cardiovascular disease
- CVD-associated pathological condition or disease in a human, preferably, in an overweight or obese human individual, and/or
- CVD cardiovascular disease
- CVD-associated pathological condition or disease in a human, preferably, in an overweight or obese human individual.
- one or more HMOs selected from the group consisting of fucosylated HMOs and core HMOs, preferably of a mixture of one or more fucosylated HMOs and one or more core HMOs, for use in, or a synthetic composition comprising an effective amount of one or more HMOs selected from the group consisting of fucosylated HMOs and core HMOs, preferably of a mixture of one or more fucosylated HMOs and one or more core HMOs, for use in, or a method for increasing the abundance of bifidobacteria in a human, preferably, in an overweight or obese human having a propensity of, or diagnosed with a cardiovascular disease (CVD).
- the HMOs suitable for the purpose according to this aspect of the invention are disclosed below.
- the invention relates in different embodiments to single HMOs as substantially pure single compounds, i.e. an HMO which grade of purity satisfies the demand of a medical or food authority for marketing, or mixtures of 2 to 5 such substantially pure HMOs, or artificial compositions comprising one to five HMOs.
- HMOs and compositions comprising thereof are described below.
- CVD cardiovascular disease
- CVD cardiovascular disease
- CVD cardiovascular disease
- the HMOs may be a single HMO or a mixture of two to five of any HMOs suitable for the purpose of the invention.
- the HMO is a fucosylated or a non-fucosylated neutral HMO.
- the invention relates to a mixture of HMOs, the mixture comprising at least a first HMO and at least a second HMO, wherein the first HMO is a fucosylated neutral HMO and the second HMO is a non-fucosylated neutral HMO.
- the mixture may comprise further a third, a forth and a fifth HMO.
- the mixture of HMOs may contain a fucosylated HMO selected from the list consisting of 2'- FL, 3-FL, DFL, LNFP-I, LNFP-II, LNFP-III, LNFP-V, LNDFH-I, LNDFH-II, LNDFH-III, FLNH-I, FLNH-II, FLNnH, FpLNH-I and F-pLNnH II, and a non-fucosylated HMO selected from the list consisting of LNT, LNnT, LNH, LNnH, pLNH and pLNnH.
- a fucosylated HMO selected from the list consisting of 2'- FL, 3-FL, DFL, LNFP-I, LNFP-II, LNFP-III, LNFP-V, LNDFH-I, LNDFH-II, LNDFH-III, FLNH-I, FLNH-II, FLNnH, FpL
- the mixture of HMOs contains a fucosylated HMO selected from the list consisting of 2'-FL, 3-FL and DFL, and a non-fucosylated HMO selected from the list consisting of LNT and LNnT; advantageously the mixture comprises 2'-FL and LNnT and/or LNT.
- the mixture of HMOs essentially consists of two neutral HMOs, e.g.
- a fucosylated HMO selected from the list consisting of 2'-FL, 3-FL, DFL, LNFP-I, LNFP-II, LNFP-III, LNFP-V, LNDFH-I, LNDFH-II, LNDFH- III, FLNH-I, FLNH-II, FLNnH, FpLNH-I and F-pLNnH II, and a non-fucosylated HMO selected from the list consisting of LNT, LNnT, LNH, LNnH, pLNH and pLNnH.
- the mixture essentially consists of a fucosylated HMO selected from the list consisting of 2'-FL, 3-FL and DFL, and a non-fucosylated HMO selected from the list consisting of LNT and LNnT; in one preferred embodiment the mixture essentially consists of 2'-FL and LNnT, in another preferred embodiment the mixture essentially consists of 2'-FL and LNT.
- a mixture of 2'-FL and LNnT may contain the amount of 2'-FL: LNnT form about 1.5 : 1 to about 4: 1 by weight.
- the invention relates to a synthetic composition for use in
- CVD cardiovascular disease
- CVD cardiovascular disease
- CVD cardiovascular disease
- HMO which may comprise a single HMO or a mixture of two to five of any HMOs suitable for the purpose of the invention as disclosed above.
- the synthetic composition can take any suitable form.
- the composition can be in the form of a nutritional composition which contains other macronutrients such as proteins, lipids or other carbohydrates (see below) .
- the synthetic composition can also be a pharmaceutical composition .
- a pharmaceutical composition contains an effective amount of HMO or an effective amount of mixture of two to five HMOs, wherein the HMOs are selected from any of described above.
- the term "effective amount" in the present content means an amount of a single HMO, or a combination of different HMOs that is capable of increasing the abundance of bifidobacteria in the gastrointestinal tract of a human individual of the invention, preferably, relative abundance of members of the Bifidobacterium adolescentis phylogenetic group in particular B. adolescentis and/or B. pseudocatenulatum .
- the pharmaceutical composition can further contain a pharmaceutically acceptable carrier, e.g. phosphate buffered saline solution, mixtures of ethanol in water, water and emulsions such as an oil/water or water/oil emulsion, as well as various wetting agents or excipients.
- a pharmaceutically acceptable carrier e.g. phosphate buffered saline solution, mixtures of ethanol in water, water and emulsions such as an oil/water or water/oil emulsion, as well as various wetting agents or excipients.
- the pharmaceutical composition can also contain other materials that do not produce an adverse, allergic or otherwise unwanted reaction when administered to humans.
- the carriers and other materials can include solvents, dispersants, coatings, absorption promoting agents, controlled release agents, and one or more inert excipients, such as starches, polyols, granulating agents, microcrystalline cellulose, diluents, lubricants, binders, and disintegrating agents.
- compositions can be administered orally, e.g. as a tablet, capsule, or pellet containing a predetermined amount, or as a powder or granules containing a predetermined concentration or a gel, paste, solution, suspension, emulsion, syrup, bolus, electuary, or slurry, in an aqueous or non-aqueous liquid, containing a predetermined concentration.
- Orally administered compositions can include binders, lubricants, inert diluents, flavouring agents, and humectants.
- Orally administered compositions such as tablets can optionally be coated and can be formulated so as to provide sustained, delayed or controlled release of the mixture therein.
- compositions can also be administered by rectal suppository, aerosol tube, naso-gastric tube or direct infusion into the GI tract or stomach.
- compositions can also include therapeutic agents most commonly prescribed for heart disease such as:
- ACE inhibitors are a type of medication that dilates (widens) arteries to lower blood pressure and make it easier for the heart to pump blood. They also block some of the harmful actions of the endocrine system that may occur with heart failure;
- Eplerenone (Inspra) and spironolactone (Aldoctone) and eplerenone are potassium-sparing diuretics. They can be prescribed to reduce the swelling and water build-up caused by heart failure. Diuretics cause the kidneys to send unneeded water and salt from the tissues and blood into the urine;
- ARBs Angiotensin II Receptor Blocker
- ARBs are used to decrease blood pressure in people with heart failure. ARBs decrease certain chemicals that narrow the blood vessels so blood can flow more easily through your body. They also decrease certain chemicals that cause salt and fluid build-up in the body;
- Beta-Blockers block the effects of adrenaline (epinephrine) and thereby improve the heart's ability to perform. They also decrease the production of harmful substances produced by the body in response to heart failure. They cause the heart to beat more slowly and with less force, lowering blood pressure;
- Calcium channel blockers are prescribed to treat angina (chest pain) and high blood pressure. Calcium channel blockers affect the movement of calcium in the cells of the heart and blood vessels. As a result, the drugs relax blood vessels and increase the supply of blood and oxygen to the heart, while reducing its workload;
- Cholesterol -Lowering Drugs Cholesterol helps your body build new cells, insulate nerves, and produce hormones. But inflammation may lead to cholesterol build-up in the walls of arteries, increasing the risk of heart attack and stroke;
- Digoxin helps an injured or weakened heart to work more efficiently and to send blood through the body. It strengthens the force of the heart muscle's contractions and may improve blood circulation; Diuretics: Diuretics, commonly known as "water pills," cause the kidneys to get rid of unneeded water and salt from the tissues and bloodstream into the urine. Getting rid of excess fluid makes it easier for your heart to pump. Diuretics are used to treat high blood pressure and reduce the swelling and water build-up caused by various medical problems, including heart failure;
- Inotropic therapy is used to stimulate an injured or weakened heart to pump harder to send blood through the body. It helps the force of the heart muscle's contractions and relaxes constricted blood vessels so blood can flow more smoothly. Inotropic therapy may also speed up the heart's rhythm;
- Potassium or Magnesium are minerals that can be lost because of increased urination when taking diuretics. Low levels in the body can be associated with abnormal heart rhythms. Some patients take them as supplements as directed by their doctor.
- Vasodilators are used to treat heart failure and control high blood pressure by relaxing the blood vessels so blood can flow more easily through the body. Vasodilators are prescribed for patients who cannot take ACE inhibitors.
- Warfarin is an anticoagulant medication. "Anti” means “against,” and “coagulant” means “causing blood clotting.” Therefore, warfarin helps prevent clots from forming in the blood.
- the pharmaceutical composition may also contain other compounds such as antibiotics, probiotics, analgesics, and anti-inflammatory agents.
- compositions for a human can be determined in a conventional manner, based upon factors such as severity of conditions of the human individual, e.g. the individual's blood pressure, immune status, body weight, age, etc.
- the invention relates to a method for
- CVD cardiovascular disease
- pathologic condition or disease in a human, preferably, wherein said human is overweight or obese;
- CVD cardiovascular disease
- CVD-associated pathologic condition or disease in a human, preferably wherein said human is overweight or obese;
- CVD cardiovascular disease
- CVD-associated pathologic condition or disease in a human, preferably, wherein said human is overweight or obese;
- HMO human milk oligosaccharide
- the invention contemplates both prophylactic and therapeutic methods of treatment depending on different embodiments.
- therapeutic method means a method co mprising treatment of disease or medical disorder by remedial agents and/or, e.g .
- prophylactic method means a method comprising a measure taken to fend off a disease or another unwanted consequence of the disease, e.g . administering an HMO or a composition of the invention to a human of the invention to reduce the propensity of or prevent development of CVD or the associated pathological condition or disease in the human.
- an HMO of the invention is administered to a human in need enteral, e.g. orally.
- invention relates to a method increasing the abundance of a bacterium of the B. adolescentis phylogenetic group, especially Bifidobacterium adolescentis and/or B.
- one or more HMOs may be any of the methods.
- one or more HMOs preferably, one to five HMOs, may be any of the methods.
- substantially pure compounds i.e. neat
- diluted e.g . in form of a solution, power or syrup, or in the form of a synthetic composition, nutritional or
- compositions as any of the described above, in one or more unit dosage forms, preferably in a single unit dosage form.
- the HMOs are, or the synthetic, nutritional or pharmaceutical, composition contains, 2'-FL and LNnT, preferably the 2'-FL: LNnT ratio is about 1.5 : 1 to about 4: 1 by weight.
- the dosage of one or more fucosylated HMOs and one or more core HMOs per administration may vary from about 2 g to about 10 g, preferably from about 3.5 g to about 7.5 g.
- the HMOs are administered in a single dosage unit containing from about 2 g to about 10 g, preferably from about 3.5 g to about 7.5 g of one of more fucosylated HMOs and one or more core HMOs.
- the patient may also additionally receive a dose of one or more species of probiotic bacteria, e.g . bifidobacteria.
- the patient is administered a daily dose of at least 2 g of the mixture of one or more fucosylated HMOs and one or more core HMOs for at least 14 days, preferably, for more than 14 days.
- a nutritional composition can contain sources of protein, lipids and/or digestible
- composition can be designed to be the sole source of nutrition or a nutritional supplement.
- Suitable protein sources include intact, hydrolysed, and partially hydrolysed protein, which can be derived from any suitable source such as milk (e.g., casein, whey), animal (e.g. meat, fish), cereal (e.g. rice, corn), and vegetable (e.g. soy, potato, pea), insect (e.g. locust) and combinations of these sources.
- milk e.g., casein, whey
- animal e.g. meat, fish
- cereal e.g. rice, corn
- vegetable e.g. soy, potato, pea
- insect e.g. locust
- Examples of the source of protein include whey protein concentrates, whey protein isolates, whey protein hydrolysates, acid caseins, sodium casemates, calcium casemates, potassium casemates, casein hydrolysates, milk protein concentrates, milk protein isolates, milk protein hydrolysates, non-fat dry milk, condensed skim milk, soy protein concentrates, soy protein isolates, soy protein hydrolysates, pea protein concentrates, pea protein isolates, pea protein hydrolysates, collagen proteins, and combinations of these sources.
- the amount of protein is preferably sufficient to provide about 5 to about 30 % of the energy of the nutritional composition; for example about 10 % to about 25 % of the energy. Within these ranges, the amount of protein can vary depending upon the nutritional needs of the intended individual.
- the nutritional compositions can also include free amino acids such as tryptophan, glutamine, tyrosine, methionine, cysteine, taurine, arginine, carnitine, threonine, serine and proline and combinations of these amino acids.
- Threonine, serine and proline are important amino acids for the production of mucin which aids gut barrier function.
- Any suitable source of other carbohydrates can be used. Examples include maltodextrin, hydrolysed or modified starch or corn starch, glucose polymers, corn syrup, corn syrup solids, rice-derived carbohydrates, sucrose, glucose, fructose, lactose, high fructose corn syrup, honey, sugar alcohols (e.g., maltitol, erythritol, sorbitol, etc.), isomaltulose, sucromalt, pullulan, potato starch, slowly-digested carbohydrates, dietary fibres such as oat fibre, soy fibre, gum arabic, sodium carboxymethylcellulose, methylcellulose, guar gum, gellan gum, locust bean gum, konjac flour, hydroxypropyl methylcellulose, tragacanth gum, karaya gum, gum acacia, chitosan, arabinogalactans, glucomannan, xanthan gum, alginate, pectin, low and high methoxy pectin, cereal
- the carbohydrate source includes low glycemic index carbohydrates having a GI score of 55 or below.
- low glycemic index carbohydrates include sucromalt,
- Fibersol(TM) inulin
- maltodextrins having a dextrose equivalence (DE) of less than
- rice syrup having a dextrose equivalence of less than 15
- fructooligosaccharides resistant starches, starches, fruit sourced fibres, vegetable sourced fibres, whole grains, beta-glucans, soy fibres, oat fibres, locust bean gum, konjac flour, hydroxy propyl methylcellulose, gum acacia, chitosan, arabinogalactans, xanthan gum, alginate, low and high methoxy pectin, carrageenan, psyllium, isomaltulose, glycerine and sugar alcohols.
- DE dextrose equivalence
- rice syrup having a dextrose equivalence of less than 15
- fructooligosaccharides resistant starches, starches, fruit sourced fibres, vegetable sourced fibres, whole grains
- the nutritional compositions can include carbohydrates in an amount sufficient to provide about 30 to about 70 % of the energy of the composition, for example about 35 to about 65 % of the energy. Within these parameters, the amount of carbohydrate can vary widely.
- Suitable lipid sources include coconut oil, fractionated coconut oil, soy oil, corn oil, olive oil, safflower oil, high oleic safflower oil, medium chain triglycerides, sunflower oil, high oleic sunflower oil, palm and palm kernel oils, palm olein, canola oil, marine oils, cottonseed oils and combinations of these oils.
- Fractionated coconut oils are a suitable source of medium chain triglycerides.
- the lipids can contain polyunsaturated fatty acids such as n-3 LC-PUFA.
- the n-3 LC-PUFA can be a C20 or a C22 n-3 fatty acid .
- n-3 LC-PUFA is docosahexanoic acid (DHA, C22 : 6, n-3) .
- the source of LC-PUFA can be, for example, egg lipids, fungal oil, low EPA fish oil or algal oil.
- the nutritional compositions can include lipids in an amount sufficient to provide about 10 to about 50 % of energy of the nutritional composition, for example about 15 to about 40 % of the energy.
- the nutritional composition preferably also includes vitamins and minerals. If the nutritional composition is intended to be a sole source of nutrition, it preferably includes a complete vitamin and mineral profile.
- vitamins include vitamins A, B-complex (such as Bl, B2, B6 and B12), C, D, E and K, niacin and acid vitamins such as pantothenic acid, folic acid and biotin.
- minerals include calcium, iron, zinc, magnesium, iodine, copper, phosphorus, manganese, potassium, chromium, molybdenum, selenium, nickel, tin, silicon, vanadium and boron .
- the nutritional composition can also include a carotenoid such as lutein, lycopene, zeaxanthin, and beta -carotene.
- a carotenoid such as lutein, lycopene, zeaxanthin, and beta -carotene.
- the total amount of carotenoid included can vary from about 0.001 pg/ml to about 10 pg/ml.
- Lutein can be included in an amount of from about 0.001 pg/ml to about 10 pg/ml, preferably from about 0.044 pg/ml to about 5 pg/ml of lutein.
- Lycopene can be included in an amount from about 0.001 pg/ml to about 10 pg/ml, preferably about 0.0185 pg/ml to about 5 pg/ml of lycopene.
- Beta-carotene can comprise from about 0.001 pg/ml to about 10 pg/ml, for example about 0.034 pg/ml to about 5 pg/ml of beta-carotene.
- the nutritional composition can also include a source of anthocyanins. This can be in the form of a fruit or a fruit extract. Particularly useful fruits and fruit extracts include plum/prune, apple, pear, strawberry, blueberry, raspberry, cherry, and their combinations.
- the nutritional composition can also contain various other conventional ingredients such as preservatives, emulsifying agents, thickening agents, buffers, fibres and prebiotics (e.g . fructooligosaccharides, galactooligosaccharides), probiotics (e.g . B. animalis subsp. lactis BB- 12, B. lactis HN019, B. lactis Bi07, B. infant is ATCC 15697, L. rhamnosus GG, L. rhamnosus HNOOI, L. acidophilus LA-5, L. acidophilus NCFM, L. fermentum CECT5716, B. longum BB536, B. longum AH 1205, B. longum AH 1206, B.
- prebiotics e.g . fructooligosaccharides, galactooligosaccharides
- probiotics e.g . B. animalis subsp. lactis BB- 12, B. lactis HN019, B
- antioxidant/anti-inflammatory compounds including tocopherols, caroteinoids, ascorbate/vitamin C, ascorbyl palmitate, polyphenols, glutathione, and superoxide dismutase (melon), other bioactive factors (e.g . growth hormones, cytokines, TFG- ⁇ ), colorants, flavours, and stabilisers, lubricants, and so forth.
- the nutritional composition can be in the form of a food, soluble powder, a liquid concentrate, or a ready-to-use formulation.
- the composition can be eaten, drunk or can be fed via a nasogastric.
- Various flavours, fibres and other additives can also be present.
- the nutritional compositions can be prepared by any commonly used manufacturing techniques for preparing nutritional compositions in solid or liquid form.
- the composition can be prepared by combining various feed solutions.
- a protein-in-fat feed solution can be prepared by heating and mixing the lipid source and then adding an emulsifier (e.g . lecithin), fat soluble vitamins, and at least a portion of the protein source while heating and stirring.
- a carbohydrate feed solution is then prepared by adding minerals, trace and ultra trace minerals, thickening or suspending agents to water while heating and stirring. The resulting solution is held for 10 minutes with continued heat and agitation before adding carbohydrates (e.g. the HMOs and digestible carbohydrate sources) .
- the resulting feed solutions are then blended together while heating and agitating and the pH adj usted to 6.6-7.0, after which the composition is subjected to high-temperature short-time processing during which the composition is heat treated, emulsified and homogenized, and then allowed to cool.
- Water soluble vitamins and ascorbic acid are added, the pH is adj usted to the desired range if necessary, flavours are added, and water is added to achieve the desired total solid level.
- the resulting solution can then be aseptically packed to form an aseptically packaged nutritional composition.
- the nutritional composition can be in ready-to-feed or concentrated liquid form.
- the composition can be spray- dried and processed and packaged as a reconstitutable powder.
- the nutritional composition can also be in the form of a food such as a nutritional bar, a yoghurt, etc. These forms can be produced using standard technologies and processes.
- the total concentration of HMOs in the liquid, by weight of the liquid is from about 0.0001 % to about 2.0 %, including from about 0.001 % to about 1.5 %, including from about 0.01 % to about 1.0 %.
- the total concentration of HMSs/HMOs in the liquid, by weight of the liquid is from about 0.0002 % to about 4.0 %, including from about 0.002 % to about 3.0 %, including from about 0.02 % to about 2.0 %.
- the synthetic composition of this invention can also be in a unit dosage form such as a capsule, tablet or sachet.
- the composition can be in a tablet form comprising the human milk oligosaccharides, and one or more additional components to aid formulation and administration, such as diluents, excipients, antioxidants, lubricants, colorants, binders, disintegrants, and the like.
- Suitable diluents, excipients, lubricants, colorants, binders, and disintegrants include polyethylene, polyvinyl chloride, ethyl cellulose, acrylate polymers and their copolymers, hydroxyethyl-cellulose, hydroxypropylmethyl-cellulose (HPMC), sodium
- PHEMA polyhydroxyethyl methacrylate
- PVA polyvinyl alcohol
- PVP polyvinyl pyrrolidone
- PEO polyethylene oxide
- PA polyacrylamide
- carrageenan sodium alginate, polycarbophil, polyacrylic acid, tragacanth, methyl cellulose, pectin, natural gums, xanthan gum, guar gum, karaya gum, hypromellose, magnesium stearate,
- Suitable antioxidants are vitamin A, carotenoids, vitamin C, vitamin E, selenium, flavonoids, polyphenols, lycopene, lutein, lignan, coenzyme Q10 ("CoQIO”) and glutathione.
- the unit dosage forms can also include various nutrients including macronutrients.
- the unit dosage forms can be administered orally, e.g. as a tablet, capsule, or pellet containing a predetermined amount, or as a powder or granules containing a predetermined concentration or a gel, paste, solution, suspension, emulsion, syrup, bolus, electuary, or slurry, in an aqueous or non-aqueous liquid, containing a predetermined concentration.
- Orally administered compositions can include binders, lubricants, inert diluents, flavouring agents, and humectants.
- Orally administered compositions such as tablets can optionally be coated and can be formulated so as to provide sustained, delayed or controlled release of the mixture therein.
- Example 1 Treating high fat diet induced obesity and diabetes
- mice 10-week-old C57BL/6J mice (100 mice) are housed in groups of five mice per cage, with free to water. The mice are divided into 10 groups of 10 mice, one control group and 9 treatment groups. All of the mice are fed a high-fat (HF) diet (60 % fat and 20 % carbohydrates
- the 9 treatment groups are each administered one of the following : a) 2'-FL, b) 3-FL, c) 3'-SL, d) 6'-SL, e) LNT, f) LNnT, g) LNFP-I, h) DSLNT and i) a combination of these saccharides.
- the control group is administered the HF diet only.
- Intraperitoneal or oral glucose tolerance tests are performed as follows : 6-h-fasted mice are injected with glucose into the peritoneal cavity ( 1 g/kg glucose, 20 % glucose solution) or by gavage (3 g/kg glucose, 66 % glucose solution) . Blood glucose is determined with a glucose meter (Roche Diagnostics) on 3.5 ⁇ blood collected from the tip of the tail vein. A total of 20 ⁇ blood is sampled 30 min before and 15 or 30 min after the glucose load to assess plasma insulin concentration.
- the intestinal permeability of 4000 Da fluorescent dextran-FITC (DX-4000-FITC) is measured .
- M ice are fasted for 6 h before given DX-44-FITC by gavage (500 mg/kg body weight, 125 mg/ml) .
- 120 ml of blood is collected from the tip of the tail vein.
- the blood is centrifuged at 4 °C, 12 000 g for 3 min.
- Plasma is diluted in an equal volume of PBS (pH 7.4) and analysed for DX- 4000-FITC concentration with a fluorescence spectrophotometer at an excitation wavelength of 485 nm and emission wavelength of 535 nm. Standard curves are obtained by diluting FITC-dextran in non-treated plasma diluted with PBS ( 1 : 3 v/v) .
- Mice are anaesthetised (ketamine/xylazine, intraperineally, 100 and 10 mg/kg, respectively) after a 5 h period of fasting, and blood samples and tissues are harvested for further analysis. Mice are killed by cervical dislocation. Liver, caecum (full and empty), muscles (vastus lateralis), and adipose tissues (mesenteric and corresponding lymph nodes, epididymal, subcutaneous and visceral) are precisely dissected and weighed and stored at - 80 °C, for further analysis.
- Total and active GLP1 are measured from blood with ELISA (M illipore, Molsheim, France) .
- the caecal contents collected post mortem from mice are stored at -80 °C.
- DNA is isolated from the caecal content samples using QIAamp DNA Stool Mini Kit. The DNA concentration of extracts is measured using NanoDrop.
- Aliquots of 100 ng of extracted DNA are subjected to PCR using the 16S rDNA universal heteroduplex analysis (HDA) primers HDA1-GC 50-CGCCCGGGGCGCGCCCCGGGCGGG- GCGGGGGCACGGGGGGGGACTCCTACGGGAGGCAGCAGT-30 and HDA2 50- TTACCGCGGCTGCTGGCA-30 (both primers are disclosed in Walter et al. Appl. Environ.
- HDA 16S rDNA universal heteroduplex analysis
- Electrophoresis is carried out at 130 V for 4-5 hours at 60 °C. Polyacrylamide gels are stained with GelRede nucleic acid stain for 45 min, destained in ultrapure water and viewed under UV light. Bands of interest are excised from gels and lysed in ultrapure water. Extracted DNA is re-amplified using the same primers and PCR conditions. To purify the bacterial DNA, PCR products are reloaded on a denaturant gradient gel followed by excision and lysis of selected bands. DNA samples recovered from lysed bands of the second DGGE are re-amplified by PCR before purification using the QIAquick PCR Purification Kit and sequenced. Species identification is done using the Ribosomal Microbiome Database Project Classifier tool.
- the V5-V6 region of 16S rRNA from caecal content DNA samples is amplified using the primers 784F 50- AGGATTAGATACCCT- GGTA-30 and 1061R 50-CRRCACGAGCTGACGAC-30 3640 (both primers are disclosed in Andersson et al. , PloS ONE 3 , e2836 (2008)) .
- Amplicons are pyrosequenced using a Roche 454 GS-FLX system. Sequences of at least 240 nucleotides and containing no more than two undetermined bases are retained for taxonomic assignment.
- the QIIME software is used for chimera check and the Greengenes database is used for classification. Bacterial diversity is determined at the phylum, family and genus levels.
- HMOs are able to change the intestinal microbiota by increasing the abundance of bifidobacteria . Additionally, HMO supplementation increased the level of GLP1 and reduced body weight and adipose tissue. The level of GLP1 negatively correlated with food intake.
- mice 10-week-old C57BL/6J mice ( 100 mice) are housed in groups of five mice per cage, with free access to food and water. The mice are divided into 10 groups of 10 mice, one control group and 9 treatment groups. All of the mice are fed a high-fat (HF) diet (60 % fat and 20 % carbohydrates [kcal/ 100 g], or an HF diet supplemented with HMO (20 g/kg of diet) for 8 weeks. Food and water intake are recorded twice a week.
- HF high-fat
- HMO 20 g/kg of diet
- the 9 treatment groups are each administered one of the following : a) 2'-FL, b) 3-FL, c) 3'-SL, d) 6'-SL, e) LNT, f) LNnT, g) LNFP-I, h) DSLNT and i) a combination of these saccharides.
- the control group is
- Intraperitoneal or oral glucose tolerance tests are performed as follows : 6-h-fasted mice are injected with glucose into the peritoneal cavity ( 1 g/kg glucose, 20 % glucose solution) or by gavage (3 g/kg glucose, 66 % glucose solution) . Blood glucose is determined with a glucose meter (Roche Diagnostics) on 3.5 ⁇ blood collected from the tip of the tail vein. A total of 20 ⁇ blood is sampled 30 min before and 15 or 30 min after the glucose load to assess plasma insulin concentration.
- the intestinal permeability of 4000 Da fluorescent dextran-FITC (DX-4000-FITC) is measured .
- M ice are fasted for 6 h before given DX-44-FITC by gavage (500 mg/kg body weight, 125 mg/ml) .
- 120 ml of blood is collected from the tip of the tail vein.
- the blood is centrifuged at 4 °C, 12 000 g for 3 min.
- Plasma is diluted in an equal volume of PBS (pH 7.4) and analysed for DX- 4000-FITC concentration with a fluorescence spectrophotometer at an excitation wavelength of 485 nm and emission wavelength of 535 nm. Standard curves are obtained by diluting FITC-dextran in non-treated plasma diluted with PBS ( 1 : 3 v/v) .
- Plasma LPS, cytokines and gut hormones are determined as follows. Plasma LPS
- Plasma cytokines interleukin (IL) la, ILlb, tumour necrosis factor (TNF) a, IL6, monocyte chemoattractant protein (MCP)- l, macrophage inflammatory protein ( ⁇ )- ⁇ , IL10, interferon (INF) c, IL15, IL18) and gut hormones (GLP1 (active), GIP (total), amylin (active), pancreatic polypeptide) are respectively determined in duplicate by using a Bio-Plex Multiplex kit, or a mouse gut hormones panel (LincoPlex), and measured by using Luminex technology, an EIA kit (GLP2 EIA kit) is used to quantify GLP2.
- IL interleukin
- TNF tumour necrosis factor
- MCP monocyte chemoattractant protein
- INF interferon
- GLP1 active
- GIP total
- amylin active
- Mice are anaesthetised (ketamine/xylazine, intraperineally, 100 and 10 mg/kg, respectively) after a 5 h period of fasting, and blood samples and tissues are harvested for further analysis. Mice are killed by cervical dislocation. Liver, caecum (full and empty), muscles (vastus lateralis), and adipose tissues (mesenteric and corresponding lymph nodes, epididymal, subcutaneous and visceral) are precisely dissected and weighed . The intestinal segments (jej unum, colon) are immersed in liquid nitrogen, and stored at -80 °C, for further analysis.
- the caecal contents collected post mortem from mice are stored at -80 °C.
- DNA is isolated from the caecal content samples using QIAamp DNA Stool Mini Kit. The DNA concentration of extracts is measured using NanoDrop. Aliquots of 100 ng of extracted DNA are subjected to PCR using the 16S rDNA universal heteroduplex analysis (HDA) primers HDA1-GC 50-CGCCCGGGGCGCGCCCCGGGCGGG- GCGGGGGCACGGGGGGGGACTCCTACGGGAGGCAGCAGT-30 and HDA2 50-
- HDA 16S rDNA universal heteroduplex analysis
- Electrophoresis is carried out at 130 V for 4-5 hours at 60 °C. Polyacrylamide gels are stained with GelRede nucleic acid stain for 45 min, destained in ultrapure water and viewed under UV light. Bands of interest are excised from gels and lysed in ultrapure water. Extracted DNA is re-amplified using the same primers and PCR conditions. To purify the bacterial DNA, PCR products are reloaded on a denaturant gradient gel followed by excision and lysis of selected bands. DNA samples recovered from lysed bands of the second DGGE are re-amplified by PCR before purification using the QIAquick PCR Purification Kit and sequenced. Species identification is done using the Ribosormal Microbiorme Database Project Classifier tool.
- the V5-V6 region of 16S rRNA from caecal content DNA samples is amplified using the primers 784F 50- AGGATTAGATACCCT- GGTA-30 and 1061R 50-CRRCACGAGCTGACGAC-30 3640 (both primers are disclosed in Andersson et al. PloS ONE 3 , e2836 (2008)) .
- Amplicons are pyrosequenced using a Roche 454 GS-FLX system. Sequences of at least 240 nucleotides and containing no more than two undetermined bases are retained for taxonomic assignment.
- the QIIME software is used for chimera check and the Greengenes database is used for classification. Bacterial diversity is determined at the phylum, family and genus levels.
- MAT mesenteric adipose tissue
- MN lymph nodes
- Quantification of bacterial DNA is performed by isolating genomic DNA from blood, MAT, MLN or intestine (contents and mucosa) . All bacterial DNA is quantified by quantitative real-time PCR targeting conserved regions of the 16S rRNA gene, with bacterial DNA as standard template for absolute quantification.
- occludin and zonula occludens- 1 (ZO- 1) tight-junction proteins are assessed. Jej unum segments are immediately removed, washed with PBS, mounted in embedding medium, and stored at -80 °C until use.
- Cryosections (5 mm) are fixed in acetone at -20 °C for 5 min for occludin and in ethanol for 30 min at room temperature and in acetone at -20 °C for 5 min for ZO- 1.
- Non-specific background is blocked by incubation with 10% bovine serum albumin (BSA) in Tris-buffered saline (TBS) and 0.3% Triton X- 100 (30 min at room temperature) .
- Sections are incubated with rabbit anti-occludin or rabbit anti-ZO- 1 ( 1 : 400 for ZO- 1 and 1 : 100 for occludin staining) for 2 h.
- Sections are washed three times for 10 min in TBS and probed with goat anti-rabbit fluorescein isothiocyante (FITC)-conj ugated antibodies (1 : 50) . Slides are washed three times for 10 min in TBS and mounted in mounting medium. Sections are visualised on a
- HMOs improve gut barrier function and reduce the metabolic inflammation and insulin resistance associated with obesity, and increase release of gut peptides, such as glucagon-like peptidel and 2 (GLP1 and GLP2) .
- 10-week-old C57BL/6J mice 100 mice are housed in groups of five mice per cage, with free water. The mice are divided into 10 groups of 10 mice, one control group and 9 treatment groups. All of the mice are fed a high-fat (HF) diet (60 % fat and 20 % carbohydrates [kcal/100 g], or an HF diet supplemented with HMO (20 g/kg of diet) for 8 weeks. Food and water intake are recorded twice a week.
- HF high-fat
- the 9 treatment groups are each administered one of the following : a) 2'-FL, b) 3-FL, c) 3'-SL, d) 6'-SL, e) LNT, f) LNnT, g) LNFP-I, h) DSLNT and i) a combination of these saccharides.
- the control group is administered the HF diet only.
- Intraperitoneal or oral glucose tolerance tests are performed as follows : 6-h-fasted mice are injected with glucose into the peritoneal cavity ( 1 g/kg glucose, 20 % glucose solution) or by gavage (3 g/kg glucose, 66 % glucose solution) . Blood glucose is determined with a glucose meter (Roche Diagnostics) on 3.5 ⁇ blood collected from the tip of the tail vein. A total of 20 ⁇ blood is sampled 30 min before and 15 or 30 min after the glucose load to assess plasma insulin concentration.
- Plasma triglyceride and cholesterol is measured from blood taken during the treatment period.
- the intestinal permeability of 4000 Da fluorescent dextran-FITC (DX-4000-FITC) is measured .
- M ice are fasted for 6 h before given DX-44-FITC by gavage (500 mg/kg body weight, 125 mg/ml) .
- 120 ml of blood is collected from the tip of the tail vein.
- the blood is centrifuged at 4 °C, 12 000 g for 3 min.
- Plasma is diluted in an equal volume of PBS (pH 7.4) and analysed for DX- 4000-FITC concentration with a fluorescence spectrophotometer at an excitation wavelength of 485 nm and emission wavelength of 535 nm. Standard curves are obtained by diluting FITC-dextran in non-treated plasma diluted with PBS ( 1 : 3 v/v) .
- Mice are anaesthetised (ketamine/xylazine, intraperineally, 100 and 10 mg/kg, respectively) after a 5 h period of fasting, blood samples and tissues are harvested for further analysis. Mice are killed by cervical dislocation. Liver, caecum (full and empty), and adipose tissues (mesenteric and corresponding lymph nodes, epididymal, subcutaneous and visceral) are precisely dissected, weighed and stored at -80 °C, for further analysis.
- Total and active GLP1 are measured from blood with ELISA (M illipore, Molsheim, France) .
- the caecal contents collected post mortem from mice are stored at -80 °C.
- DNA is isolated from the caecal content samples using QIAamp DNA Stool Mini Kit. The DNA concentration of extracts is measured using NanoDrop.
- Aliquots of 100 ng of extracted DNA are subjected to PCR using the 16S rDNA universal heteroduplex analysis (HDA) primers HDA1-GC 50-CGCCCGGGGCGCGCCCCGGGCGGG- GCGGGGGCACGGGGGGGGACTCCTACGGGAGGCAGCAGT-30 and HDA2 50- TTACCGCGGCTGCTGGCA-30 (both primers are disclosed in Walter et al. Appl. Environ.
- HDA 16S rDNA universal heteroduplex analysis
- Electrophoresis is carried out at 130 V for 4-5 hours at 60 °C. Polyacrylamide gels are stained with GelRede nucleic acid stain for 45 min, destained in ultrapure water and viewed under UV light. Bands of interest are excised from gels and lysed in ultrapure water. Extracted DNA is re-amplified using the same primers and PCR conditions. To purify the bacterial DNA, PCR products are reloaded on a denaturant gradient gel followed by excision and lysis of selected bands. DNA samples recovered from lysed bands of the second DGGE are re-amplified by PCR before purification using the QIAquick PCR Purification Kit and sequenced. Species
- the V5-V6 region of 16S rRNA from caecal content DNA samples is amplified using the primers 784F 50- AGGATTAGATACCCT- GGTA-30 and 1061R 50-CRRCACGAGCTGACGAC-30 3640 (both primers are disclosed in Andersson et al. PloS ONE 3 , e2836 (2008)) .
- Amplicons are pyrosequenced using a Roche 454 GS-FLX system. Sequences of at least 240 nucleotides and containing no more than two undetermined bases are retained for taxonomic assignment.
- the QIIME software is used for chimera check and the Greengenes database is used for classification. Bacterial diversity is determined at the phylum, family and genus levels.
- HMOs are able to change the intestinal microbiota by increasing the abundance of bifidobacteria . Additionally, HMO supplementation reduces cholesterol, body weight, fat accumulation and glucose tolerance.
- mice Six-week-old ob/ob mice ( 120 mice) on C57BL/6 background are housed in a controlled environment ( 12 h daylight cycle) in groups of 2 mice/cage, and kept with free access to food and drinking water. The mice are separated into 10 groups of 10 mice, one control group and 9 treatment groups. One group is fed a control diet, and the 9 treatment groups each receive a control diets containing one of the following HMOs (20 g/kg of diet) for five weeks: a) 2'-FL, b) 3-FL, c) 3'-SL, d) 6'-SL, e) LNT, f) LNnT, g) LNFP-I, h) DSLNT, and i) a combination of these saccharides. Fresh food is given daily.
- the investigational products contain 4.5 grams of either 2'-FL alone or a combination of 2'-FL and LNnT in a 4: 1 ratio while the placebo product contains 4.5 grams of glucose. All products are in powder form in a unit dosage container.
- the patients are eligible to participate if: they are between 5 and 12 years of age, have a BMI SDS (Standard Deviation Score) of ⁇ 2.0 and are enrolled in the childhood obesity treatment program at the Children's Obesity Clinic. All recruited patients and their representatives are able and willing to understand and comply with the study procedures.
- BMI SDS Standard Deviation Score
- Patients are excluded if: they have participated in a clinical study one month prior to the screening visit and throughout the study; have any gastrointestinal disease(s) that may cause symptoms or may interfere with the trial outcome; have other severe disease(s) such as malignancy, kidney disease or neurological disease; have psychiatric disease; have used highly dosed probiotic supplements (yoghurt allowed) 3 months prior to screening and throughout the study; have consumed antibiotic drugs 3 months prior to screening and throughout the study; and consume on a regular basis medication that might interfere with symptom evaluation 2 weeks prior to screening and throughout the study.
- Eligibility criteria are checked and for children who are enrolled to the study, medical history and concomitant medication are registered. A physical examination is done and pubertal staging is determined. Blood pressure, pulse rate, height and bodyweight are measured, and body composition is determined by a DXA (dual energy x-ray absorptiometry)-scan and bioimpedance. BMI SDS is calculated, waist and hip circumferences measured and food intake registered. Fasting blood samples are collected for safety and biomarker studies and for biobanking.
- the serum from the blood samples is transferred to cryotubes and stored at -80° C.
- the following biomarkers are measured; Lipopolysaccharides (LPS), hsCRP, free fatty acids, total cholesterol, HDL, LDL, HbAlc, glucose, insulin, triglycerides, TNF-a, IL- ⁇ , IL-6, IL-8, IL-10, GLP1, GLP2, Adiponectin, and Zonulin.
- faecal samples Equipment for collecting faecal samples is distributed.
- the faecal samples are stored at -80° C until analysis.
- Microbiological analysis is performed on the faecal samples using 16S rRNA gene sequencing.
- GSRS Gastrointestinal Symptom Rating Scale
- BSFS Bristol Stool Form Scales
- faecal samples are collected and equipment for collection of new samples is distributed.
- BSFS is collected and new BSFS is distributed.
- Study products are distributed together with a compliance form (diary). Patients and their representatives are reminded to follow the healthy dietary habits.
- the study runs for 8 weeks with the patients consuming either a placebo or one of two investigational products daily. Patients are instructed to consume the products in the morning with breakfast. Compliance is monitored via a compliance form (diary) to be filled in daily.
- each patient has a visit with the medical team. Patients and their representatives are asked about adverse events and any changes in the patient's usual medication. Study products and compliance forms are collected to check compliance.
- BSFS and faecal samples are collected and equipment for collection of new samples is distributed. A physical examination is done and pubertal staging is determined. Blood pressure, pulse rate, height and bodyweight are measured, and body composition is determined by a DXA (dual energy x-ray absorptiometry)-scan and bioimpedance. BMI SDS is calculated, waist and hip circumferences measured and food intake registered. Fasting blood samples are collected for safety and biomarker studies and for biobanking, and equipment for collecting faecal samples is distributed. The GSRS questionnaire is completed on site by the participating child's representative(s).
- BMI SDS Absorptiometry-scan and bioimpedance.
- BMI SDS is calculated, waist and hip circumferences measured and food intake registered.
- Fasting blood samples are collected for safety and biomarker studies and for biobanking. Faecal samples are collected.
- results show that oral ingestion of HMOs modulate the intestinal microbiota, and specifically stimulate the growth of bifidobacteria.
- the blood biomarker analysis indicates that the patients given the investigational products have increased levels of GLP1.
- the level of GLP1 correlated positively with the abundance of bifidobacteria.
- HMOs are able to increase bifidobacteria and change the intestinal environment, and by this, increasing the level of GLP1 in obese children.
- results also show that oral ingestion of HMOs modulate the intestinal microbiota, and specifically stimulate the growth of bifidobacteria, particularly species belonging to the B. adolescentis phylogenetic group, and change the SCFA profile.
- the blood biomarker analysis indicated that the patients given the investigational products have a lipid profile with lower triglyceride levels and higher high-density lipoprotein cholesterol. Additionally, the blood pressure and body composition is decreased . The abundance of bifidobacteria correlates negatively with the level of low-density lipoprotein cholesterol and positively with the level of high-density lipoprotein cholesterol. Collectively, HMOs are able to increase bifidobacteria and change the intestinal environment, and by this, improve the lipid profile, hypertension and body composition, all incidence reducing the risk of CVD.
- the patients receiving the intervention product have lower HOMA-IR scores. Further, the patients given the investigational products show a greater reduction of body fat, body weight and BMI SDS as compared to the placebo group.
- the blood biomarker analysis indicates that the patients given the investigational products have increased levels of GLP1 and GLP2, reduced levels of metabolic endotoxemia and inflammatory markers and reduced gut permeability indicating an improved mucosal barrier compared to the placebo.
- the faecal analysis indicates that the patients given the investigational products have reduced bacterial dysbiosis and a higher level of bifidobacteria compared to the placebo, particularly
- a ready to feed nutritional composition is prepared from water, maltodextrin, milk protein concentrate, Sucromalt, glycerine, cocoa powder, soy protein isolate, fructose, high oleic safflower oil, soy oil, canola oil, plant sterol esters, HMOs, soy lecithin, magnesium chloride, calcium phosphate, carrageenan, sodium ascorbate, potassium citrate, sodium phosphate, calcium citrate, choline chloride, potassium chloride, sodium citrate, magnesium oxide, taurine, L-carnitine, alpha-tocopheryl acetate, zinc sulphate, ferrous sulphate, niacinamide, calcium pantothenate, vitamin A palmitate, citric acid, manganese sulphate, pyridoxine hydrochloride, vitamin D3, copper sulphate, thiamine mononitrate, riboflavin, beta carotene, folic acid, biotin, potassium iodide
- the composition has an energy density of 0.8 kcal/ml with an energy distribution (% of kcal) as follows : protein : 20 %, carbohydrate : 48 %, fat: 32 %.
- a tablet is prepared from HMO, hydroxypropyl methylcellulose, sodium alginate, gum, microcrystalline cellulose, colloidal silicon dioxide, and magnesium stearate. All raw materials except the magnesium stearate are placed into a high shear granulator and premixed . Water is sprayed onto the premix while continuing to mix at 300 rpm. The granulate is transferred to a fluidised bed drier and dried at 75 °C. The dried powder is sieved and sized using a mill. The resulting powder is then lubricated with magnesium stearate and pressed into tablets. The tablets each contain 325 mg of HMO. The tablets each have a weight of 750 mg.
- a capsule is prepared by filling about 1 g of HMO into a 000 gelatine capsule using a filing machine. The capsules are then closed. The HMO are in free flowing, powder form.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/183,431 US10987368B2 (en) | 2014-12-08 | 2016-06-15 | Synthetic composition for preventing or treating CVD |
US15/183,391 US10835544B2 (en) | 2014-12-08 | 2016-06-15 | Synthetic composition for regulating satiety |
US15/183,404 US10881674B2 (en) | 2014-12-08 | 2016-06-15 | Synthetic composition for treating metabolic disorders |
PCT/DK2017/050198 WO2017215721A1 (en) | 2016-06-15 | 2017-06-15 | Synthetic compositions comprising human milk oligosaccharides for use γν the prevention and treatment of disorders |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3471562A1 true EP3471562A1 (en) | 2019-04-24 |
EP3471562A4 EP3471562A4 (en) | 2020-07-29 |
Family
ID=60663363
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP17812794.0A Withdrawn EP3471562A4 (en) | 2016-06-15 | 2017-06-15 | Synthetic compositions comprising human milk oligosaccharides for use the prevention and treatment of disorders |
Country Status (2)
Country | Link |
---|---|
EP (1) | EP3471562A4 (en) |
WO (1) | WO2017215721A1 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021094993A1 (en) * | 2019-11-14 | 2021-05-20 | Glycom A/S | Synthetic composition for balancing the bile acid profile in the intestine |
WO2021123253A1 (en) * | 2019-12-19 | 2021-06-24 | Basf Se | Composition for the treatment of (pre)hyperglycemia and/or associated morbidities thereto |
AU2021212325A1 (en) * | 2020-01-31 | 2022-07-28 | N.V. Nutricia | Nutritional composition for use in gut maturation |
AU2021241800A1 (en) * | 2020-03-25 | 2022-08-04 | Frieslandcampina Nederland B.V. | Compositions comprising one or more HMO's with a core of LacNac-Lac |
TW202233201A (en) * | 2020-12-16 | 2022-09-01 | 荷蘭商弗里斯蘭康必奶荷蘭有限公司 | Synthetic compositions comprising lnfp iii and lsta |
CN114145353A (en) * | 2021-11-30 | 2022-03-08 | 内蒙古伊利实业集团股份有限公司 | Formula milk powder capable of improving intestinal microenvironment health and preparation method and application thereof |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5906982A (en) * | 1997-03-31 | 1999-05-25 | Abbott Laboratories | Nutritional formulations containing Lacto-N-neoTetraose |
BRPI0620451A2 (en) * | 2005-12-23 | 2011-04-12 | Nutricia Nv | use of a composition comprising a digestible lipid, protein and carbohydrate component |
EP2072052A1 (en) * | 2007-12-17 | 2009-06-24 | Nestec S.A. | Prevention of opportunistic infections in immune-compromised subjects |
AR071550A1 (en) * | 2007-12-21 | 2010-06-30 | Nutricia Nv | USE OF NON-DIGERABLE CARBOHYDRATES TO IMPROVE INTESTINAL MICROBIOTA |
WO2011119023A1 (en) * | 2010-03-26 | 2011-09-29 | N.V. Nutricia | Low protein infant formula with increased essential amino acids |
US9636367B2 (en) * | 2011-10-18 | 2017-05-02 | Nestec S.A. | Composition for use in increasing insulin sensitivity and/or reducing insulin resistance |
EP2999358B1 (en) * | 2013-05-22 | 2021-07-07 | Glycom A/S | Synthetic mixture of oligosaccharides for the treating a microbiota of a mammal |
US20150305385A1 (en) * | 2014-04-25 | 2015-10-29 | Mead Johnson Nutrition Company | Pediatric nutritional composition with human milk oligosaccahrides, prebiotics and probiotics |
EP3229812A4 (en) * | 2014-12-08 | 2018-10-03 | Glycom A/S | Synthetic composition for treating metabolic disorders |
EP3407892A1 (en) * | 2016-01-26 | 2018-12-05 | Nestec S.A. | Compositions comprising sialylated oligosaccharides for use in infants or young children to prevent later in life obesity or related comorbidities and promote a healthy growth |
AU2017211272B2 (en) * | 2016-01-26 | 2022-04-21 | Société des Produits Nestlé S.A. | Human milk oligosaccharides for health benefits by prevention of premature adiposity rebound |
EP3407897A1 (en) * | 2016-01-26 | 2018-12-05 | Nestec S.A. | Compositions comprising human milk oligosaccharides for use in infants or young children to prevent or treat a health disorder by increasing glp-1 secretion |
MX2018008953A (en) * | 2016-01-26 | 2018-09-03 | Nestec Sa | Compositions comprising 2fl and lnnt for use in infants or young children to prevent later in life obesity or related comorbidities. |
-
2017
- 2017-06-15 WO PCT/DK2017/050198 patent/WO2017215721A1/en unknown
- 2017-06-15 EP EP17812794.0A patent/EP3471562A4/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
EP3471562A4 (en) | 2020-07-29 |
WO2017215721A1 (en) | 2017-12-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11529364B2 (en) | Synthetic composition for treating metabolic disorders | |
JP7301093B2 (en) | Synthetic compositions and methods for treatment of irritable bowel syndrome | |
US10987368B2 (en) | Synthetic composition for preventing or treating CVD | |
EP3471562A1 (en) | Synthetic compositions comprising human milk oligosaccharides for use the prevention and treatment of disorders | |
WO2017046711A1 (en) | Synthetic composition for microbiota modulation | |
US11291677B2 (en) | Synthetic composition for microbiota modulation | |
BR112020010843A2 (en) | human milk oligosaccharides and synthetic compositions for modulation of the microbiota | |
US11890293B2 (en) | Synthetic composition for treating metabolic disorders | |
EP3458073A1 (en) | Synthetic composition | |
EP3493686B1 (en) | Nutritional compositions and infant formulas comprising a mix of oligosaccharides and optionally bifidobacterium lactis for preventing, treating or reducing the severity of non-rotavirus-associated diarrhoea | |
WO2018157900A1 (en) | Synthetic composition for microbiota modulation | |
CA3081496A1 (en) | Mixture of hmos for reducing or preventing fatigue | |
EP3630123A1 (en) | Synthetic composition comprising one or more human milk oligosaccharides (hmos) | |
US20220378809A1 (en) | Synthetic composition for balancing the bile acid profile in the intestine | |
US10835544B2 (en) | Synthetic composition for regulating satiety | |
EP3716984A1 (en) | Mixture of hmos for treating wheat sensitivity | |
JP2022535718A (en) | Human milk oligosaccharides for use in treating symptoms in patients suffering from non-celiac wheat and/or gluten sensitivity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20190115 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 31/702 20060101ALI20200123BHEP Ipc: A61P 3/04 20060101ALN20200123BHEP Ipc: A23L 33/125 20160101AFI20200123BHEP Ipc: A61P 3/10 20060101ALN20200123BHEP Ipc: A61P 9/10 20060101ALN20200123BHEP |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20200626 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 9/10 20060101ALN20200622BHEP Ipc: A61P 3/04 20060101ALN20200622BHEP Ipc: A61P 3/10 20060101ALN20200622BHEP Ipc: A23L 33/125 20160101AFI20200622BHEP Ipc: A61K 31/702 20060101ALI20200622BHEP |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20230922 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20240203 |